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Abstract
Hantaviruses are a genus of rodent-borne viruses within the family Bunyaviridae. Humans are a dead end host,
wherein Hantavirus infection can cause severe, potentially fatal clinical disease. The specific mechanisms of
Hantavirus infection are poorly understood. In particular, the host proteins and entry pathways that mediate
Hantavirus entry are not yet known. We set out to identify these factors using two separate, but potentially
complementary methods, focusing our efforts on a representative Hantavirus - Andes Virus (ANDV). First,
using a high-throughput, luciferase-based assay with ANDV pseudotypes, we screened a siRNA library of
~9000 genes to identify host factors involved in ANDV infection. We ultimately identified 9 genes important
for Hantavirus entry including SREBF2, a transcriptional regulator of cholesterol uptake. At the same time, a
separate genetic screen performed by a collaborator independently identified SREBF2 and other members of
the same cholesterol regulatory pathway (SCAP, S1P, S2P). Further experiments using siRNAs and small
molecule inhibitors with both pseudotypes and live ANDV, identified an important role for cholesterol in
ANDV internalization. Second, we attempted to use the highly characterized NCI-60 panel of cell lines to
identify genes whose expression is correlated with ANDV entry. We infected a panel of 32 cell lines with
ANDV pseudovirions in a FACS-based assay to measure relative permissiveness and then correlated
permissiveness with gene expression using cDNA microarray data for these cell lines. Using this analysis we
identified a list of 33 genes that potentially play a role in ANDV entry. Although initial follow-up experiments
have failed to validate a subset of these genes, further experiments will be needed to fully test the entire list of
candidate genes. Further analysis and experiments combining this list of genes with the cholesterol-
dependence of ANDV entry may lead to further identification of specific pathways and factors utilized by
Hantaviruses for infection and possibly potential targets for therapy.
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IDENTIFYING HOST FACTORS IMPORTANT FOR HANTAVIRUS ENTRY 
 
Josiah Enoch Petersen 
 
Robert W. Doms 
 
 
Hantaviruses are a genus of rodent-borne viruses within the family Bunyaviridae. 
Humans are a dead end host, wherein Hantavirus infection can cause severe, potentially 
fatal clinical disease.  The specific mechanisms of Hantavirus infection are poorly 
understood.  In particular, the host proteins and entry pathways that mediate Hantavirus 
entry are not yet known.  We set out to identify these factors using two separate, but 
potentially complementary methods, focusing our efforts on a representative Hantavirus - 
Andes Virus (ANDV).  First, using a high-throughput, luciferase-based assay with 
ANDV pseudotypes, we screened a siRNA library of ~9000 genes to identify host factors 
involved in ANDV infection.  We ultimately identified 9 genes important for Hantavirus 
entry including SREBF2, a transcriptional regulator of cholesterol uptake.  At the same 
time, a separate genetic screen performed by a collaborator independently identified 
SREBF2 and other members of the same cholesterol regulatory pathway (SCAP, S1P, 
S2P).  Further experiments using siRNAs and small molecule inhibitors with both 
pseudotypes and live ANDV, identified an important role for cholesterol in ANDV 
internalization.  Second, we attempted to use the highly characterized NCI-60 panel of 
cell lines to identify genes whose expression is correlated with ANDV entry.  We 
infected a panel of 32 cell lines with ANDV pseudovirions in a FACS-based assay to 
measure relative permissiveness and then correlated permissiveness with gene expression 
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using cDNA microarray data for these cell lines.   Using this analysis we identified a list 
of 33 genes that potentially play a role in ANDV entry.  Although initial follow-up 
experiments have failed to validate a subset of these genes, further experiments will be 
needed to fully test the entire list of candidate genes.  Further analysis and experiments 
combining this list of genes with the cholesterol-dependence of ANDV entry may lead to 
further identification of specific pathways and factors utilized by Hantaviruses for 
infection and possibly potential targets for therapy. 
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Hantavirus Background 
Hantaviruses comprise a genus of rodent-borne viruses within the family 
Bunyaviridae. To date, more than 30 different Hantaviruses have been identified, 
including Andes Virus (ANDV), Sin Nombre Virus (SNV), Hantaan Virus (HTNV), and 
Puumala Virus (PUUV).  Hantaviruses are divided into two categories - Old World 
Hantaviruses of Europe and Asia such as HTNV and PUUV and New World 
Hantaviruses of North and South America such as ANDV and SNV (Zeier et al., 2005).  
While other Bunyaviruses are transmitted by mosquito and tick vectors, Hantaviruses are 
carried by small rodent hosts such as mice and voles.  Humans become infected via 
inhalation of aerosolized virus particles from rodent excreta (Schmaljohn & Nichol, 
2007). 
Each Hantavirus species has a specific natural host that also determines its 
geographical distribution (Zeier et al., 2005).  In its natural host, Hantaviruses establish a 
chronic infection with variable pathology.  Typically, infection by HTNV and PUUV is 
characterized by a transient viremia lasting ~10 days followed by several months of 
detectable viral antigen in several organs, including the liver and kidney, but most 
prominently within the lung (Lee, et al., 1981; Yanagihara, Amyx, & Gajdusek, 1985).  
Infectious virus can be shed in the urine for up to year in the case of HTNV; however, no 
gross pathology has been identified in this chronic setting, though pathophysiological 
studies have been limited (Lee, et al., 1981).  In contrast, deer mice naturally infected 
with SNV have detectable viral antigen in the lung, liver, and kidney with alveolar edema 
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and mononuclear infiltrates present in the lung, but the time course of this pathology and 
its long-term effects on the host remain undetermined (Netski, Thran, & St Jeor, 1999). 
Humans are typically a dead-end host for these viruses.  Evidence of human-to-
human transmission has been demonstrated only for ANDV and is rare (Padula et al., 
1998).  In contrast to the chronic infection seen in their rodent hosts, Hantaviruses cause 
two clinical syndromes in humans.  Hemorrhagic Fever with Renal Symptoms (HFRS) is 
caused by Old World Hantaviruses and, after an initial 2-4 week incubation period, 
clinically manifests in five overlapping phases.  The prodrome is characterized by an 
influenza-like illness including fever, chills, malaise, and abdominal pain lasting 3-7 
days.  The hypotensive phase, also notable for thrombocytopenia and petechiae, lasts up 
to 2 days and can result in fatal shock in severe cases.  This is followed by a 3-7 day 
oliguric phase due to renal failure.  The subsequent diuretic phase lasts days to weeks and 
is an indicator of beginning recovery.  Finally, in the convalescent phase of recovery, 
clinical signs and symptoms return to normal (Bi, Formenty, & Roth, 2008; Ferluga & 
Vizjak, 2008; Krüger, Ulrich, & Lundkvist A, 2001).  There are 150,000 to 200,000 
documented cases of HFRS each year throughout Europe and Asia with a 1–12 % 
mortality rate for those cases, depending on the virus (Ho Wang Lee, 1996).  Studies in 
Europe and Asia estimate a seroprevalence of 1-10% for both HTNV and PUUV in their 
endemic regions (Bi et al., 2008).  Given the non-specific nature of the prodrome, it is 
estimated that at least 5-20% of infections are subclinical or asymptomatic (Bi et al., 
2008). 
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Hantavirus-Associated Cardiopulmonary Syndrome (HCPS) is associated with 
New World Hantaviruses and is characterized by an incubation period and prodrome 
similar to that of HFRS.  After the prodrome, there is a cardiopulmonary phase notable 
for rapid onset pulmonary edema and cardiogenic shock in severe cases.  HCPS has a 
mortality rate of nearly 40%, with most deaths occurring in this phase.  The diuretic and 
convalescent phases of recovery mirror those of HFRS (Bi et al., 2008; Jonsson, Hooper, 
& Mertz, 2008; Krüger et al., 2001).  While there is an incidence of only 200 reported 
cases/year of HCPS throughout North and South America, seroprevalence in the United 
States is reportedly ~1% in endemic areas while studies have estimated ANDV 
seroprevalence at 14% in endemic areas of Brazil and as high as 40% in endemic areas of 
Argentina and Paraguay, suggesting that most infections are asymptomatic, subclinical, 
or undiagnosed (Campos et al., 2003; Ferrer et al., 1998; Fulhorst et al., 2007; Vitek et 
al., 1996).   
Both HRFS and HCPS are vascular leak syndromes with similar pathology but 
different tissue tropism.  Pathology in HCPS is localized almost exclusively to the lung 
and immunohistochemistry on SNV patient autopsy samples demonstrates viral antigen is 
most abundant and widespread in the endothelium of the pulmonary microvasculature 
(Zaki et al., 1995). However, virus antigen can also be found at lower levels in multiple 
organs including kidney, spleen, and lymph nodes.  Viral antigen in the renal 
endothelium during HCPS is evident but much less extensive than that seen in the lung 
(Zaki et al., 1995).  In HFRS, viral antigen is found in the renal glomerular epithelium 
and endothelium of the renal microvasculature (Groen et al., 1996; Kim et al., 1993). 
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Levels of cytokines such as TNF-a, IL-2, IL-6, and IL-10 have been reported as elevated 
in both HFRS and HCPS patients, however the role of these cytokines in the 
pathophysiology of the disease is unclear (Borges et al., 2006; Mackow & Gavrilovskaya, 
2009).  The difference in tropism for these syndromes could be driven by a number of 
factors including host receptor expression, virus entry, viral replication, and evasion of 
cell defenses. 
Current treatment for these syndromes consists only of supportive therapy such as 
extracorporeal membrane oxygenation (ECMO) for severe HCPS, dialysis for HFRS, and 
careful monitoring of fluid status (Jonsson et al., 2008).  Currently, there is no FDA-
approved vaccine (Krüger et al., 2001).  A randomized, placebo-controlled clinical trial 
of ribavirin treatment of HFRS found it to be effective if given during prodromal stages 
of infection (Huggins et al., 1991).  In contrast, a similar trial found Ribavirin to be 
ineffective for treatment of HCPS, at least in the cardiopulmonary stages of infection.  
This trial was halted early due to low subject enrollment so it is unclear how conclusive 
these results may actually be (Mertz et al., 2004).  It should also be noted that studies 
have shown ribavirin to be effective in inhibiting both Old and New World viruses in 
vitro and that ribavirin is effective in treating ANDV infection in a Syrian hamster model 
– the only current in vivo animal model for HCPS – suggesting that ribavirin remains a 
plausible treatment for HCPS (Safronetz, Haddock, Feldmann, Ebihara, & Feldmann, 
2011).   
There are currently few research models for studying Hantaviruses.  Hantaviruses 
are considered Category C Bioterror agents and have been classified as BSL-3 viruses in 
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cell culture and as BSL-4 viruses in live animal models (Chosewood & Wilson, 2009).  A 
Syrian hamster model of ANDV mimics the clinical and pathological findings of human 
HCPS (Hooper, Larsen, Custer, & Schmaljohn, 2001).  Similarly, a cynomolgus macaque 
model of PUUV infection produces a mild HFRS-like syndrome similar to that seen in 
humans (Plyusnin, Vaheri, & Lundkvist, 2002; Sironen et al., 2008).  In light of the 
difficulty and cost involved in these models, in vitro cell culture methods are commonly 
used to study molecular aspects of these viruses. 
 
General Virus Entry 
 Viruses are obligate, intracellular parasites that must utilize host cell machinery to 
successfully replicate.  The initial entry steps of the bunyavirus life cycle require 
successful attachment, membrane fusion, uncoating, and release of viral genetic material 
into the host cell.  For membrane-enveloped viruses in general, entry is initiated by virus 
binding to the cell surface, usually mediated by the virus glycoprotein binding to specific 
host receptors and/or attachment factors at the cell surface.  For our purposes, a receptor 
is a cell surface molecule, commonly a host protein or carbohydrate moiety, required by 
the virus for direct binding and entry in at least some cell types.  After binding, the 
receptor may also mediate further entry steps including signaling, endocytosis, and 
conformational changes in the virus glycoprotein. For example, HIV binding to its 
receptor, CD4, induces conformational changes in the HIV glycoprotein that expose the 
binding site for its co-receptor.  Co-receptor binding induces the HIV glycoprotein to 
mediate fusion with the host cell membrane.  In contrast, an attachment factor is a cell 
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surface molecule that enhances binding of the virus to the cell surface, but is not 
necessarily required for entry.  The C-type lectin DC-SIGN, for example, has been shown 
to enhance HIV binding, but is not required for entry (Wilen, Tilton, & Doms, 2012). 
 The virus glycoproteins responsible for fusion are generally divided into Class I 
and Class II fusion proteins, though less-defined Class III proteins also exist.  Class I 
fusion proteins, like those of influenza and HIV, exist as trimers that form spikes on the 
virus surface and are primed for activation by a proteolytic cleavage event.  Activation of 
fusion induces a series of conformational changes in the virus glycoprotein(s) in which a 
hydrophobic domain, known as the fusion peptide, extends and inserts itself into the host 
cell membrane.   The trimeric glycoprotein folds back onto itself to form a six-helix 
bundle, bringing the viral and host membranes into close apposition and forcing fusion to 
occur.  In contrast, Class II fusion proteins, such as those of the Flavivirus family, exist as 
homodimers that lay parallel to the virus surface.  Upon activation, these proteins 
rearrange to form trimeric spike structures and from that point, Class II fusion proteins 
essentially follow a similar series of steps as Class I fusion proteins to force fusion of 
host and virus membranes (Kielian & Rey, 2006; White et al., 2008). 
 Upon binding to the cell, viruses commonly use host endocytic pathways, such as 
clathrin-mediated endocytosis, caveolin-mediated endocytosis, and macropinocytosis to 
traffic to subcellular compartments.  This ensures that viruses trigger fusion and 
uncoating only after gaining entry into the cell.  Many viruses use the low pH of 
intracellular compartments as a trigger for the conformational changes required for fusion 
(Morizono & Chen, 2011).  Other triggers can include host proteases that are present only 
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in endosomal compartments, such as cathepsins, that activate the viral glycoprotein for 
fusion (Chandran et al., 2005). Some viruses, such as HIV, enter cells via endocytosis 
despite not requiring endosomal triggers for fusion suggesting endocytosis of virions may 
provide other advantages (Miyauchi et al., 2009).  
  Cells have several mechanisms for taking up extracellular content such as 
phagocytosis, macropinocytosis, clathrin-mediated endocytosis, caveolin-mediated 
endocytosis, and other pathways that remain undefined.  Use of these pathways for viral 
entry can provide advantages such as immediate evasion of immune surveillance, 
delivery to acidic compartments for activation for pH-dependent fusion, and intracellular 
trafficking closer to subcompartments important for viral replication.   While there are 
multiple pathways for virus entry, the clathrin-mediated, caveolin-mediated, and 
macropinocytic pathways have been the most extensively studied.   
Clathrin is a cytoplasmic protein composed of heavy and light chains that 
combine to form a triskelion structure.  Upon recruitment to the plasma membrane, either 
constitutively or by active signaling, clathrin complexes form cage-like lattice structures 
that cause invaginations of the cellular membranes forming clathrin-coated pits (Doherty 
& McMahon, 2009).  Clathrin interacts with the cellular membrane proteins via adaptor 
proteins such as AP-2 and Eps15, both of which are essential for clathrin-coated pit 
formation (Benmerah et al., 1999; Doherty & McMahon, 2009).  Clathrin-coated vesicles 
are formed by separation of the clathrin-coated pit from the membrane by dynamin, a 
GTPase that polymerizes around the neck of the budding pit, drives scission of the 
vesicle from the membrane to form clathrin-coated vesicles (Doherty & McMahon, 2009; 
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Praefcke & McMahon, 2004).  Rab proteins then direct vesicle trafficking to early and, 
eventually, late endosomes (Mercer, Schelhaas, & Helenius, 2010).  Influenza A and 
Vesicular Stomatitis Virus are two of several viruses that have been reported to use the 
clathrin pathway for uptake (Johannsdottir et al., 2009; Mercer et al., 2010; Rust et al., 
2004). 
Caveolae are flask-shaped invaginations of the plasma membrane, 50-80nm in 
diameter, that play an important role in many cell processes including cell signaling and 
endocytosis.  Caveolae are formed by the transmembrane protein caveolin-1 (Rothberg et 
al., 1992).  These proteins are necessary and sufficient for caveolae formation. Activation 
of caveolar endocytosis involves signaling, actin polymerization, and cytoskeletal 
reorganization (Pelkmans, Püntener, & Helenius, 2002).  Like clathrin-mediated 
endocytosis, dynamin is required for vesicle formation (Henley et al., 1998; Oh, 
McIntosh, & Schnitzer, 1998).  Caveolins are detergent insoluble and caveolin-mediated 
endocytosis occurs from cholesterol-rich lipid raft domains of the plasma membrane 
(Brown & London, 1998).  Cholesterol-depleting drugs such as Methyl-β-Cyclodextrin 
(MβCD) and filipin take advantage of this property to inhibit caveolar endocytosis 
(Sieczkarski & Whittaker, 2002).  SV40 is commonly cited as a virus that requires 
specifically caveolar endocytosis though the exact role caveolin has become unclear in 
recent years (Damm et al., 2005; Engel et al., 2011; Pelkmans et al., 2002). 
Macropinocytosis is an endocytic pathway important for cell growth and fluid-
phase uptake.  During macropinocytosis, in response to appropriate extracellular signals, 
the plasma membrane undergoes significant membrane ruffling that folds back onto the 
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cell surface engulfing fluid and molecules surrounding the cell.  Fusion of the ruffled 
membranes brings this fluid into intracellular compartments (Mercer & Helenius, 2009).  
Entry via this pathway is most well characterized for vaccinia virus where binding to the 
cell induces a complex signaling cascade leading to cytoskeletal rearrangements and 
ultimately uptake into intracellular compartments (Mercer & Helenius, 2008).  
 
Hantavirus Entry Factors 
Hantaviruses contain tri-segmented, negative-sense, single-strand RNA genomes.  
The small (S), medium (M), and large (L) segments encode the nucleocapsid (N), two 
type I transmembrane glycoproteins (Gn/Gc), and the RNA-dependent RNA polymerase 
(RdRp), respectively (Schmaljohn & Nichol, 2007).  Gn and Gc are co-translationally 
cleaved from a single precursor and interact to form ordered structures on the surface of 
the virion (Huiskonen et al., 2010; Kamrud, 1994; Löber et al, 2001).  Gn and Gc can be 
expressed individually, but co-expression is required for ER-to-Golgi translocation 
(Deyde et al., 2005; Ruusala et al., 1992; Shi & Elliott, 2002; Spiropoulou et al., 2003).  
While the role for each glycoprotein in entry is unclear, Gc has been proposed to be a 
class II fusion protein based on computational protein modeling studies (Tischler et al., 
2005).   
 The Hantavirus receptor, if one exists, is not clearly defined.  A series of studies 
identified β3 integrin as important for entry of several pathogenic Hantaviruses, including 
ANDV, SNV, HTNV, PUUV, Seoul Virus, and New York-1 Virus (Gavrilovskaya et al., 
1999; Gavrilovskaya et al., 1998; Matthys et al., 2010; Mou et al., 2006; Raymond et al., 
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2005). Pre-treatment of cells with anti-β3 integrin antibodies or with vitronectin, the 
endogenous ligand for β3 integrin, inhibits infection by pathogenic hantaviruses 
(Gavrilovskaya et al., 1999; Gavrilovskaya et al., 1998).  Infection is inhibited by pre-
treatment of virus with a soluble form of β3 integrin and expression of β3 integrin can 
rescue infection in resistant CHO cells (Gavrilovskaya et al., 1999; Gavrilovskaya et al., 
1998; Raymond et al., 2005).  Binding assays have demonstrated a direct interaction 
between Hantaviruses and Plexin-Semaphorin-Integrin domain of the inactive 
conformation of β3 integrin (Raymond et al., 2005). Notably, β1 integrin, but not β3 
integrin, was found to be important for the non-pathogenic Prospect Hill Virus 
(Gavrilovskaya et al., 1999;  Gavrilovskaya et al., 1998). 
 Despite previously published data, studies from our own lab have shown that β3 
integrin expression alone does not determine a cell’s susceptibility to entry (Higa et al., 
2012; Ray et al., 2010).  Using a Hantavirus-VSV pseudotype system (described in detail 
in Chapter 2), our lab demonstrated that 293T cells are highly permissive to Hantavirus 
infection but are β3 integrin-deficient.  β3 integrin-deficient SupT1 cells were shown to 
be non-permissive to infection due to a block in entry; however, this defect was not 
rescued by expression of β3 integrin (Higa et al., 2012).  Interestingly, β3 integrin-
deficient K562 cells are permissive to Hantavirus entry, but expression of β3 integrin 
modestly increases infection 2-fold (Ray et al., 2010).  Because of this, the role of β3 
integrin and reasons for the discrepancy between our data and previous publications 
remain undetermined. 
 12 
The GPI-anchored membrane protein, Decay-Accelerating Factor (DAF), has also 
been shown to play a role in Hantavirus entry, specifically in the context of polarized 
epithelial cells (Krautkrämer & Zeier, 2008).  Treatment of the polarized Vero C1008 cell 
line with DAF-specific antibodies inhibited infection by both HTNV and PUUV; and 
infection by HTNV was inhibited by pre-treatment of HTNV with soluble DAF 
(Krautkrämer & Zeier, 2008).  Coincidentally, another previous study by a different 
group, while also demonstrating the role of β3 integrin in HTNV infection, showed an 
interaction of HTNV with an unidentified 70kDa protein – the same molecular weight as 
DAF (Mou et al., 2006). 
In total, these studies suggest that β3 integrin and DAF may play a role in 
Hantavirus entry, but the full mechanisms remain unclear.  β3 integrin is a particularly 
attractive putative receptor given its role in endothelial cell function and naturally 
occurring hemorrhagic syndromes (Hodivala-Dilke et al., 1999; Maeshima, Colorado, & 
Kalluri, 2000).  Hantaviruses bind β3 integrin, but binding is specific for the bent, 
inactive conformation of the integrin and seems to actually inhibit its function making the 
integrin role in entry uncertain (Gavrilovskaya et al., 2002; Mackow & Gavrilovskaya, 
2009; Raymond et al., 2005). How β3 integrin and DAF interact is also unclear.  DAF 
has been shown to play an important role for Coxsackie virus wherein binding to DAF 
traffics viral particles to tight junctions to interact with its receptor, CAR (Coyne & 
Bergelson, 2006).  DAF could have a similar function here but this possibility has not 
been addressed.  
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It is known that Hantaviruses require low pH (~6.0) for infection of host cells, 
similar to other Bunyaviruses (Lozach et al., 2010; McCaughey et al., 1999; Ogino et al., 
2004).  Few studies have directly addressed entry pathways used to reach low-pH 
compartments and the results have been mixed. Using drugs and dominant-negative 
mutants, these studies have indicated that HTNV utilizes a clathrin-dependent, dynamin-
dependent mechanism for entry based on inhibition by chlorpromazine, sucrose, and a 
dominant-negative dynamin mutant (Jin et al., 2002; Ramanathan & Jonsson, 2008).  In 
these studies, PMA and filipin, two inhibitors of caveolin-mediated endocytosis, had no 
effect on HTNV infection.  However, at least one study has shown that HTNV infection 
can also be inhibited by the cholesterol-sequestering agent MβCD, a drug commonly 
used to inhibit caveolar endocytosis from lipid rafts (Krautkrämer & Zeier, 2008).  
ANDV seems to be unaffected by perturbations of either clathrin or caveolin 
(Ramanathan & Jonsson, 2008).  Nevertheless, given only a small number of published 
studies using relatively non-specific drug inhibitors, it is difficult to say definitively what 
pathways these viruses utilize. 
Identifying the molecular determinants of Hantavirus entry, including receptors, 
attachment factors, signaling molecules, and entry pathways is crucial for understanding 
how these viruses function.  Defining the entry pathways and viral glycoprotein 
determinants that mediate Hantavirus entry could explain cellular tropism in these cells 
and also highlight differences between HCPS- and HFRS-associated viruses.  These 
results would be useful to direct future studies of Hantavirus entry factors as targets of 
anti-viral treatments for Hantavirus infection.   
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Abstract 
 The mechanisms and host factors utilized by Hantaviruses for entry into cells are 
not yet known.  We set out to identify these factors and pathways for a representative 
Hantavirus, Andes Virus (ANDV).  We optimized and performed a high-throughput, 
luciferase-based siRNA screen of ~9,000 genes for effects on ANDV glycoprotein-
mediated entry using a VSV∆G pseudotype system at BSL-2 conditions.  Using this 
method we identified 9 genes with a potential role in ANDV entry including SREBF2, a 
transcriptional regulator of the cholesterol uptake pathway.  At the same time, a separate 
genetic screen in a human haploid cell line identified SREBF2 and further identified the 
other members of its regulatory cascade (SCAP, S1P, and S2P), independently verifying 
our result.   
Follow-up experiments using a Hantavirus-VSV pseudotype system showed 
inhibition of SREBF2 had a significant effect on ANDV entry with little to no effect on 
other Hantaviruses.  Likewise, CHO cell mutants lacking SCAP, S1P, and S2P were non-
permissive to infection relative to wild-type cells.  Use of a small molecule inhibitor of 
S1P (PF-429242) also inhibited ANDV entry.  The cholesterol-sequestering molecule 
methyl-β-cyclodextrin (MβCD) inhibited infection by several Hantaviruses, including 
ANDV, up to 100-fold while the cholesterol-independent virus VSV remained 
unaffected.  Lastly, these pseudotype infection results with the small molecules PF-
429242 and MβCD were corroborated using live, replication-competent, wild-type 
ANDV in Vero E6 cells, validating both the importance of the SREBF2 pathway and the 
Hantavirus-VSV pseudotype system used to identify it. 
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Introduction 
 RNA interference (RNAi) provides a method to inhibit the expression of an 
individual gene to identify what role, if any, that gene may play in a biological process.  
When applied in the form of a high-throughput, large-scale siRNA screen, thousands of 
genes can be tested at a time.   This approach has been previously applied to the complex 
interplay between viruses and their hosts, leading to the identification of host proteins 
involved in anti-viral defense mechanisms as well as those the virus utilizes for 
successful infection (Cherry et al., 2005; Coyne et al., 2011; Hao et al., 2008; Krishnan et 
al., 2008; Panda et al., 2011; Sabin et al., 2009; Sessions et al., 2009).  We sought to use a 
siRNA screen to identify host factors that play a role in Hantavirus entry.   
 For our screen, we studied a single, representative Hantavirus (ANDV) hoping to 
identify a subset of important genes with the intent to use follow-up experiments to 
determine if those host factors were specific to ANDV or were applicable to the entire 
Hantavirus family.  We chose to focus on ANDV because it is a highly fatal New World 
Hantavirus with close homology to other domestic Hantaviruses such as SNV 
(Schmaljohn & Hjelle, 1997).  Additionally, it is the only Hantavirus with a previously 
described live animal model in Syrian hamsters that could be potentially be used in future 
experiments (Hooper, Larsen, Custer, & Schmaljohn, 2001). 
 Because ANDV is a BSL-3 virus in cell culture, we optimized a high-throughput, 
luciferase-based assay in human HEK293T cells for screening in BSL-2 conditions.  
Although RNAi screening is more robust in Drosophila cell systems, we developed 
assays using human cells because Hantaviruses do not use an insect intermediate during 
 27 
any stage of the life cycle.  To measure infection, we used a non-replicating pseudovirion 
system in which the glycoprotein of Andes virus was pseudotyped in trans onto a 
Vesicular Stomatitis virus (VSV) construct wherein the gene for the native glycoprotein 
(VSV-G) was replaced with a Renilla Luciferase (rLuc) reporter, hereafter referred to as 
ANDV-VSV∆G*rLuc.  This construct has been previously described (Ray et. al. 2010).   
Because this construct cannot replicate, our assay measures only ANDV glycoprotein-
mediated entry and the transcription/replication required for rLuc expression.  Later 
events, including budding and second-round infection, play no role. 
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Results 
ANDV-VSV∆G*rLuc infection showed a direct correlation of rLuc activity to the 
amount of input virus across a 4-log titration of virus (Figure 2-1A).   For the screen, we 
used a concentration of virus that correlated to ~4% infection based on 
immunofluorescence staining for VSV-M protein.  ANDV-VSV∆G*rLuc was 
additionally tested in neutralization assays with ANDV-specific sera to validate ANDV 
glycoprotein-mediated entry.  To account for cell viability in our assay, we developed a 
HEK293T cell line stably expressing Firefly Luciferase (ffLuc) in which ffLuc activity 
served as a measure of cell number.  For this 293T-ffLuc cell line, ffLuc activity was 
reproducibly correlated with the number of cells plated across a ~3-log dilution range that 
included the number of cells per well used in our assay at the higher end to ensure that 
decreases in cell number could be measured accurately (Figure 2-1B). 
A number of siRNA controls were used to optimize and validate our assay.  
AllStars negative control siRNA (Qiagen) was used as a non-targeting control. AllStars 
Hs Death siRNA (Qiagen), a proprietary siRNA sequence likely targeting an anti-
apoptotic pathway, was used as a cytotoxic positive control for decreased cell viability.  
This Death siRNA can be used for visual, in addition to luciferase-based, assessment of 
siRNA knock down efficiency.  siRNAs targeting ffLuc and rLuc were used as positive 
controls specific to each luciferase reporter.  The siRNA targeting ffLuc is a previously 
validated sequence obtained from Ambion.  The siRNA targeting rLuc is a pool of 2 
 
Figure 2-1:  Titration with ANDV
ffLuc cells were infected with ANDV
undiluted concentration.  Infection was linear across a 4
RLUs mean ± SEM, n=2). 
dilutions from 1.28x105 cells/well
expression were linear across a nearly
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infection represents ~5x10
decreases in cell number/cell viability.
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custom sequences designed and validated by our lab.  As an additional positive control 
against a host gene required for infection, we used a siRNA pool targeting ATP6V0C, a 
component of the endosomal proton pump complex required for pH-dependent entry of  
ANDV.  The concentrations of siRNA and transfection reagent were titrated to maximize 
the effects of control siRNAs at 3 days post-transfection without affecting cell viability.  
Furthermore, the assay was carefully controlled such that the effects of control siRNAs 
on rLuc and ffLuc activity remained consistent for all wells, plates, and biological 
replicates across multiple days. 
We screened the Ambion Druggable Genome library (9,102 genes) in a 384-well 
format.  Four siRNAs/gene were plated in a 2x2 format (2 pools of 2 unique siRNAs per 
pool).  siRNAs were reverse-transfected into 293T-ffLuc cells and infected with ANDV-
VSV∆G*rLuc at 72 hours post-transfection.  At 24 hours post-infection, luciferase 
activity, quantified as relative light units (RLU), for cell viability and infection were 
measured in each well using the Dual-GLO luciferase system (Promega) (Figure 2-2). 
All Stars non-targeting control siRNA had no effect on cell viability or infection 
compared to normal, untreated cells (data not shown).  In contrast, the cytotoxic Death 
control had a >5-fold effect on both cell viability and infection as expected (Figure 2-3).  
Infection as measured by rLuc expression was reproducibly decreased 3-5 fold by 
siRNAs targeting either rLuc or ATP6V0C when compared to the non-targeting control 
(Figure 2-3).  The siRNA targeting ffLuc inhibited ffLuc activity 5-fold relative to the 
non-targeting control.  This ffLuc siRNA also reproducibly inhibited rLuc activity by 
~20% for reasons that have not been determined (Figure 2-3).  This decrease, while 
 Figure 2-2:  Schematic of 
 
   
 
siRNA screen. 
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Figure 2-3: siRNA controls in primary siRNA screen.   Data represents mean for all 
siRNA controls present in the primary screen and RLUs are presented as percent relative 
to negative Control.  Infection is represented by rLuc.  Cell viability is represented by 
ffLuc.  The Death siRNA inhibited both cell viability and infection.  The siRNA targeting 
ffLuc inhibited ffLuc expression, while also having a minor, unexplained effect on rLuc 
expression.  The siRNAs targeting rLuc and ATP6V0C had no effect on cell viability, 
though rLuc expression and infection were significantly inhibited.  >97% of these 
controls were appropriately identified in the primary screen using a z-score <-1.5 cutoff. 
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statistically significant relative to the non-targeting control, was not large enough to be 
identified as a hit in our screen by the criteria listed below. In the primary screen, these 
controls were plated in triplicate on each plate and >97% were correctly identified as hits 
or not hits, confirming the reproducibility of the assay. 
For each plate, robust Z scores were calculated for both cell viability and infection 
using the median and interquartile range for log-transformed RLUs.  Genes were 
identified as hits with an infection Z score < -1.5 in both siRNA pools such that at least 2 
unique siRNAs inhibited infection.   siRNAs were considered cytotoxic and excluded 
with a viability Z score < -2 in both pools.  Based on these criteria, 105 genes were 
identified as important for infection when knocked down (Table 2-1).  Of note, an 
additional 28 genes were identified as anti-viral, however, given our interest only in those 
host factors important for entry, these were not validated in follow-up. 
We selected a subset of 96 of the 105 potential required host factors for further 
validation in a secondary screen using 3 unique, un-pooled siRNAs per gene (Ambion).  
The 9 genes that were not selected for secondary screening were excluded to avoid 
redundancy (e.g. multiple members of the proteasome complex), to avoid genes unlikely 
to pay a role in entry (e.g. nuclear pore proteins), or because they were independently 
tested prior to secondary screening (Table 2-2).   The 96 selected genes were screened 
with ANDV-VSV∆G*rLuc in 3 independent replicates. Genes were identified as 
validated if at least one additional siRNA impacted infection with a robust Z score < -1.3 
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for infection normalized to cell number.  We validated 33 genes as important for 
infection – a validation rate of 31% of tested hits.   
Up to this point, our assay had measured both ANDV glycoprotein-dependent entry and 
replication of the VSV construct.  In order to differentiate genes important for ANDV 
glycoprotein-mediated entry from those related to replication of the VSV∆G*rLuc core, 
these siRNAs were additionally screened with the same construct bearing the VSV-G 
glycoprotein in trans (VSV-G-VSV∆G*rLuc).   Any gene that also inhibited infection by 
this construct was assumed to have an effect on post-entry replication and considered 
non-specific to the ANDV glycoprotein (Table 2-2, green).  Of those 34 validated genes, 
9 were specific to the ANDV-VSV∆G*rLuc construct, suggesting these are important for 
ANDV glycoprotein-mediated entry (Table 2-2, yellow). 
Of the host factors identified as ANDV-specific, we chose to focus on the role of 
Sterol Regulatory Element Binding Protein 2 (SREBF2), an important component of the 
sterol regulatory pathway.  When cholesterol levels in the cell are low, the transcription 
factor SREBF2 activates several genes known as Sterol Responsive Elements (SREs) to 
restore cholesterol levels to normal levels.  These SREs include cholesterol biosynthesis 
genes such as HMG-CoA synthase and HMG-CoA reductase, as well as cholesterol 
scavenging genes such as the Low-Density Lipoprotein Receptor (LDL-R) (Brown & 
Goldstein, 1997; Horton, Goldstein, & Brown, 2002).   
SREBF2 contains a basic helix-loop-helix DNA-binding domain at its N-terminal facing 
the cytosol followed by two transmembrane domains that anchor the protein in the 
endoplasmic reticulum (ER) membrane and a regulatory domain at the C-terminus.  
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SREBF2 Cleavage Activating Protein (SCAP) acts as a chaperone binding SREBF2 in 
the membrane and inducing a protein conformation that is retained in the ER.  SCAP 
contains 8 transmembrane domains, which are believed to serve as the cholesterol-
sensing mechanism for this protein, and a WD domain that interacts with the regulatory 
domain of SREBF2.  When cholesterol levels are low, SCAP and SREBF2 dissociate and 
allow SREBF2 to traffic to the Golgi where it encounters two proteases – Membrane- 
Bound Transcription Factor Peptidase, Site 1 (MBTPS1) and Site 2 (MBTPS1) – 
commonly referred to as Site 1 Protease (S1P) and Site 2 Protease (S2P).   SREBF2 is 
sequentially cleaved by S1P and S2P releasing DNA-binding domain to for transport to 
the nucleus (Brown & Goldstein, 1997; Horton et al., 2002; Hua, Nohturfft, Goldstein, & 
Brown, 1996; Sakai et al., 1996). 
 Cholesterol metabolism is also controlled by another SREBP termed SREBP1.  
There are two different forms of this transcription factor that are produced from the same 
gene by differential transcription start sites producing SREBP1a and SREBP1c.  
SREBP1a activates transcription of multiple genes including those in the fatty acid and 
cholesterol synthesis pathways.  In contrast, SREBP1c is an activator of the fatty acid 
synthesis pathway while SREBF2 activates genes of the cholesterol synthesis pathway.  
Together these genes control the cellular response to variances in cholesterol content of 
the cell (Brown & Goldstein, 1997; Horton et al., 2002). 
To confirm the role of SREBF2 in ANDV infection, we used siRNA to 
knockdown SREBF2 expression in 293T cells.  SREBF2 knockdown after 3 days was 
confirmed by western blot and, although not quantified, nearly complete (Figure 2-4A). 
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In contrast, non-targeting control siRNA had no effect on SREBF2 expression.  GAPDH 
was used as a loading control and its expression was unaffected by siRNA treatment.   
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Table 2-1:  Primary Screen Hits 
 
PRO-VIRAL GENES Robust Z-score 
Gene Information Infection (rLuc) Cell Viability (ffLuc) 
Gene Symbol 
Entrez Gene 
ID Gene Name 
siRNA 
AB 
siRNA 
CD 
siRNA 
AB 
siRNA 
CD 
AANAT 15 arylalkylamine N-acetyltransferase -1.7445 -1.8387 0.4593 -0.0847 
ACSL6 23305 acyl-CoA synthetase long-chain family member 6 -2.9320 -1.6386 -1.0238 -0.3947 
AKR1C4 1109 
aldo-keto reductase family 1, member C4 (chlordecone 
reductase; 3-alpha hydroxysteroid dehydrogenase, type I; 
dihydrodiol dehydrogenase 4) -1.6612 -1.8485 -1.9964 -0.0239 
AMFR 267 autocrine motility factor receptor -2.2815 -2.0190 -2.4187 -0.7862 
ANAPC10 10393 anaphase promoting complex subunit 10 -2.2541 -3.6735 0.9705 -0.8557 
ANKK1 255239 ankyrin repeat and kinase domain containing 1 -2.1480 -1.9339 0.5722 0.3824 
ATP6V0C 527 ATPase, H+ transporting, lysosomal 16kDa, V0 subunit c -2.0221 -1.6271 -1.0088 -0.6156 
ATP6V1D 51382 ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D -2.3152 -1.5821 -2.0720 0.8608 
CABP7 164633 calcium binding protein 7 -2.6393 -2.8944 -1.0715 -1.6923 
CASP7 840 caspase 7, apoptosis-related cysteine protease -1.6076 -1.6456 2.8694 0.1550 
CCL16 6360 chemokine (C-C motif) ligand 16 -1.6025 -2.3021 -0.6186 -2.6372 
CCT8 10694 chaperonin containing TCP1, subunit 8 (theta) -2.3112 -2.1612 0.3760 -1.1550 
CES2 8824 carboxylesterase 2 (intestine, liver) -2.0581 -2.2652 -2.6597 -0.9854 
CKM 1158 creatine kinase, muscle -2.1959 -1.6454 0.4294 -1.3399 
CLK4 57396 CDC-like kinase 4 -1.8008 -1.8496 -0.2448 -1.8300 
CLSTN3 9746 calsyntenin 3 -2.1361 -2.1153 -2.1801 0.0086 
COX7B 1349 cytochrome c oxidase subunit VIIb -1.6615 -1.5333 -1.0599 -1.1093 
CPN1 1369 carboxypeptidase N, polypeptide 1, 50kD -1.6985 -2.2771 1.4674 0.8962 
DNPEP 23549 aspartyl aminopeptidase -1.5115 -1.7084 -0.5280 -0.5990 
DUSP14 11072 dual specificity phosphatase 14 -1.6455 -3.4894 1.8175 -0.9617 
ERBB3 2065 
v-erb-b2 erythroblastic leukemia viral oncogene homolog 
3 (avian) -1.6024 -1.7395 -0.4498 0.3343 
EVI1 2122 ecotropic viral integration site 1 -1.5260 -1.6846 0.0887 -4.4278 
FGB 2244 fibrinogen, B beta polypeptide -1.7904 -1.5586 -0.5068 -2.0673 
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FXYD3 5349 FXYD domain containing ion transport regulator 3 -2.5744 -2.2738 -3.1630 1.1584 
GALNT10 55568 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 10 (GalNAc-T10) -1.9234 -3.8461 -0.9809 -2.6778 
GPR1 2825 G protein-coupled receptor 1 -2.8108 -2.6998 -1.2999 -3.6264 
GPR158 57512 G protein-coupled receptor 158 -1.5940 -1.8012 -1.8792 -1.3271 
GSTM4 2948 glutathione S-transferase M4 -1.6622 -2.4119 -1.8543 -0.4476 
HDAC7 51564 histone deacetylase 7A -1.6559 -1.5840 2.2970 -0.1637 
HIATL1 84641 FLJ14753 -2.0548 -2.4687 -0.3794 0.2842 
HRH2 3274 histamine receptor H2 -2.2579 -1.7392 -2.3659 0.0187 
HS3ST1 9957 heparan sulfate (glucosamine) 3-O-sulfotransferase 1 -1.9756 -2.6483 -1.6703 -2.0820 
HSPA2 3306 heat shock 70kDa protein 2 -1.7338 -1.8257 -0.8546 -1.1867 
IKZF4 64375 zinc finger protein, subfamily 1A, 4 (Eos) -1.5362 -1.9939 1.0310 -2.7860 
INPP5F 22876 inositol polyphosphate-5-phosphatase F -1.5294 -1.5719 1.2519 -0.3351 
IQGAP3 128239 IQ motif containing GTPase activating protein 3 -1.7776 -2.9044 -1.3630 -2.9656 
JARID1C 8242 Smcy homolog, X-linked (mouse) -1.9057 -1.8169 -0.0658 -0.1564 
KCNK3 3777 potassium channel, subfamily K, member 3 -1.7463 -2.1455 -0.3596 -0.4460 
LGR6 59352 
leucine-rich repeat-containing G protein-coupled receptor 
6 -2.4309 -1.6136 -1.0032 -0.4220 
LHX1 3975 LIM homeobox 1 -1.8477 -1.5204 -0.1377 -0.2907 
LILRA2 11027 
leukocyte immunoglobulin-like receptor, subfamily A (with 
TM domain), member 2 -3.7040 -2.1238 -3.0771 -1.9485 
MCAT 27349 MT -2.1356 -1.7674 2.0628 -1.2202 
NAP1L4 4676 nucleosome assembly protein 1-like 4 -2.5703 -1.5600 1.0843 0.8455 
NAT5 51126 N-acetyltransferase 5 (ARD1 homolog, S. cerevisiae) -1.7363 -2.5181 -1.3443 -3.2661 
NDUFA10 4705 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 
10, 42kDa -2.0921 -3.5261 -0.2618 -3.6652 
NEUROD4 58158 neurogenic differentiation 4 -1.5676 -1.9702 -2.0999 0.0483 
NUDT3 11165 
nudix (nucleoside diphosphate linked moiety X)-type motif 
3 -1.9329 -2.5455 -1.9172 -2.0853 
ORM1 5004 orosomucoid 1 -2.7694 -2.2524 -0.7682 -0.0079 
OXSR1 9943 oxidative-stress responsive 1 -1.9984 -1.6961 0.3508 -0.4646 
PELO 53918 pelota homolog (Drosophila) -1.8620 -1.8544 -0.6132 -1.2850 
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PHF15 23338 PHD finger protein 15 -3.0638 -1.6857 -1.5684 -0.6254 
PHF19 26147 PHD finger protein 19 -3.4517 -2.7478 -3.3786 -1.9222 
PLA2G2F 64600 phospholipase A2, group IIF -2.0218 -2.4215 0.5067 -1.7973 
PMPCB 9512 peptidase (mitochondrial processing) beta -2.7467 -1.5940 -1.3894 -0.8876 
POLA1 5422 polymerase (DNA directed), alpha -1.5139 -1.8853 -1.7969 -1.7307 
POLR2E 5434 polymerase (RNA) II (DNA directed) polypeptide E, 25kDa -1.6747 -2.2376 -1.5015 -2.2150 
POLR2I 5438 
polymerase (RNA) II (DNA directed) polypeptide I, 
14.5kDa -2.0885 -2.9971 -1.5957 -0.8462 
PPA1 5464 pyrophosphatase (inorganic) -1.7219 -1.5076 -0.6931 -1.3843 
PRKCD 5580 protein kinase C, delta -1.7280 -1.8897 -0.5666 -2.0298 
PRPF8 10594 PRP8 pre-mRNA processing factor 8 homolog (yeast) -2.6040 -2.2261 0.1755 -0.5708 
PSMC3 5702 
proteasome (prosome, macropain) 26S subunit, ATPase, 
3 -2.4584 -1.7105 -0.8214 -1.1687 
PSMC4 5704 
proteasome (prosome, macropain) 26S subunit, ATPase, 
4 -2.5207 -2.5854 0.4265 0.5436 
PSMD14 10213 
proteasome (prosome, macropain) 26S subunit, non-
ATPase, 14 -2.1260 -2.3014 -0.3281 -0.1378 
PSMD2 5708 
proteasome (prosome, macropain) 26S subunit, non-
ATPase, 2 -2.2367 -4.4147 -1.7128 -2.7911 
PSMD7 5713 
proteasome (prosome, macropain) 26S subunit, non-
ATPase, 7 (Mov34 homolog) -1.6145 -1.8300 -0.1691 0.1760 
PTGES 9536 prostaglandin E synthase -1.7872 -3.8754 -0.4844 -3.0985 
PTGS2 5743 
prostaglandin-endoperoxide synthase 2 (prostaglandin 
G/H synthase and cyclooxygenase) -1.6794 -2.1339 2.0080 -2.1886 
QPCT 25797 glutaminyl-peptide cyclotransferase (glutaminyl cyclase) -1.8569 -1.8135 -2.4749 0.3896 
RASL12 51285 RAS-like, family 12 -1.6243 -1.9594 -0.2020 -0.8443 
RBM8A 9939 RNA binding motif protein 8A -2.8634 -2.6086 -1.3114 -1.2257 
RCN3 57333 reticulocalbin 3, EF-hand calcium binding domain -4.1216 -1.7570 -1.1023 -0.6710 
SAG 6295 S-antigen; retina and pineal gland (arrestin) -1.5311 -2.2162 0.7459 0.3007 
SAP18 10284 sin3-associated polypeptide, 18kDa -1.8688 -2.1324 -1.5234 -2.2679 
SCAM-1 10174 SCAM-1 -2.0344 -2.9091 -0.0090 -1.8508 
SIN3B 23309 SIN3 homolog B, transcription regulator (yeast) -3.7205 -1.6615 -1.7902 -1.1091 
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SIRT2 22933 
sirtuin (silent mating type information regulation 2 
homolog) 2 (S. cerevisiae) -1.6663 -1.6363 -1.6317 -1.5483 
SLC16A6 9120 
solute carrier family 16 (monocarboxylic acid 
transporters), member 6 -1.6967 -1.7793 -1.2575 2.6658 
SLC25A30 253512 solute carrier family 25, member 30 -2.0898 -1.9536 0.0031 -0.9944 
SLC2A2 6514 
solute carrier family 2 (facilitated glucose transporter), 
member 2 -1.5973 -1.6142 -0.7556 -1.7224 
SNRPB 6628 small nuclear ribonucleoprotein polypeptides B and B1 -1.8876 -1.9726 1.0482 -1.5199 
SNRPD3 6634 small nuclear ribonucleoprotein D3 polypeptide 18kDa -4.2688 -3.7524 0.8249 -1.8733 
SNW1 22938 SKI interacting protein -2.1703 -2.9961 -1.2706 2.2000 
SREBF2 6721 sterol regulatory element binding transcription factor 2 -1.5736 -2.5435 0.0531 -1.3474 
SRM 6723 spermidine synthase -1.6847 -1.6671 -1.7509 0.4925 
ST3GAL2 6483 ST3 beta-galactoside alpha-2,3-sialyltransferase 2 -3.2096 -1.5752 -0.2761 -0.4941 
SWAP70 23075 SWAP70 -1.7161 -1.5378 -0.8085 -1.8705 
TEAD3 7005 TEA domain family member 3 -1.9484 -1.5949 -1.9210 0.9224 
THY1 7070 Thy-1 cell surface antigen -1.5831 -2.6437 -0.5665 -0.9801 
TLR9 54106 toll-like receptor 9 -2.6056 -2.7980 -0.4297 -0.7089 
TNFRSF10B 8795 tumor necrosis factor receptor superfamily, member 10b -1.6233 -1.9151 -3.1227 -0.4402 
TNNI3 7137 troponin I, cardiac -2.1365 -2.0233 0.1603 -1.0362 
TPX2 22974 
TPX2, microtubule-associated protein homolog (Xenopus 
laevis) -3.1960 -1.7231 -4.1864 -1.7029 
TSG101 7251 tumor susceptibility gene 101 -2.8671 -1.8442 -0.8754 -3.2220 
UBE2V2 7336 ubiquitin-conjugating enzyme E2 variant 2 -3.0620 -1.8349 -1.4438 -1.7046 
UBR2 23304 ubiquitin protein ligase E3 component n-recognin 2 -1.8997 -1.8578 -2.3162 2.4487 
UQCR10 29796 HSPC051 -2.7491 -1.7954 -3.2143 -0.7028 
VIL1 7429 villin 1 -1.8104 -1.7719 -0.5358 -2.3373 
VPS16 64601 vacuolar protein sorting 16 (yeast) -1.9595 -2.3029 -2.3004 -0.9899 
WARP 64856 WARP -2.7708 -3.5446 -1.4077 -5.1221 
WFDC5 149708 WAP four-disulfide core domain 5 -3.5688 -3.1969 -2.6682 -0.1250 
ZIC5 85416 Zic family member 5 (odd-paired homolog, Drosophila) -1.5386 -1.5845 0.6410 -1.6426 
ZNF462 58499 zinc finger protein 462 -2.0677 -1.7126 -0.5157 -1.0945 
ZNF496 84838 zinc finger protein 496 -1.6002 -1.6832 -0.2493 0.3541 
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ZNF676 163223 zinc finger protein 676 -2.0063 -1.5323 -2.7780 -0.6398 
ZNF81 347344 zinc finger protein 81 (HFZ20) -1.7552 -1.9183 0.0267 1.1855 
       
ANTI-VIRAL GENES Robust Z-score 
Gene Information Infection (rLuc) Cell Viability (ffLuc) 
Gene Symbol 
Entrez Gene 
ID Gene Name 
siRNA 
AB 
siRNA 
CD 
siRNA 
AB 
siRNA 
CD 
ACSL5 51703 acyl-CoA synthetase long-chain family member 5 1.5640 1.6176 0.7888 0.6317 
ADRBK2 157 adrenergic, beta, receptor kinase 2 1.6139 2.8476 1.2855 1.6346 
CDA 978 cytidine deaminase 1.8382 1.6841 -0.5637 -0.0108 
CHD4 1108 chromodomain helicase DNA binding protein 4 1.8588 1.6337 -2.3027 -0.1849 
DHX36 170506 DEAH (Asp-Glu-Ala-His) box polypeptide 36 1.7697 1.7856 0.2362 1.2008 
EPHX1 2052 epoxide hydrolase 1, microsomal (xenobiotic) 1.9573 1.9134 0.5367 0.2362 
HTR3C 170572 
5-hydroxytryptamine (serotonin) receptor 3, family 
member C 1.7854 1.7160 0.7477 2.6167 
ITGA10 8515 integrin, alpha 10 1.5535 1.6311 -1.5506 1.6349 
KCNV1 27012 potassium channel, subfamily V, member 1 1.5332 1.6801 -0.8102 -0.3127 
LEPREL1 55214 leprecan-like 1 1.8420 1.9297 -0.1684 0.2395 
LOC283846   LOC283846 1.5686 1.6113 0.8871 -0.7712 
MORC4 79710 zinc finger, CW type with coiled-coil domain 2 1.6248 2.2005 0.3300 1.5230 
NTNG1 22854 netrin G1 1.6695 1.6720 -0.5929 0.9028 
PABPC5 140886 poly(A) binding protein, cytoplasmic 5 1.7017 1.5465 0.7039 1.1594 
PDGFD 80310 platelet derived growth factor D 1.6984 1.9706 1.5253 0.4448 
POU4F2 5458 POU domain, class 4, transcription factor 2 2.3626 1.6423 0.7281 0.5472 
RHEBL1 121268 Ras homolog enriched in brain like 1 1.9004 1.8235 1.6201 -1.3197 
RNF185 91445 ring finger protein 185 2.3333 1.5592 0.2708 0.0097 
SMARCC2 6601 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily c, member 2 1.8271 1.7745 0.5716 -0.1492 
STX16 8675 syntaxin 16 2.2907 1.5384 0.3112 -0.1360 
STX3A 6809 syntaxin 3A 2.2758 1.5732 -0.2517 0.1987 
SYT1 6857 synaptotagmin I 3.1152 2.0516 -0.1243 0.4064 
SYT11 23208 synaptotagmin XI 2.4768 1.5631 1.0236 0.9273 
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SYTL1 84958 synaptotagmin-like 1 1.6662 1.7745 0.9616 0.0548 
TRIM55 84675 tripartite motif-containing 55 1.8717 2.2529 0.3765 1.6398 
ZC3H15 55854 zinc finger CCCH-type containing 15 1.8161 1.7414 0.4310 0.4249 
ZNF258 9204 zinc finger protein 258 1.6724 1.5042 0.6763 2.7772 
ZNF600 162966 zinc finger protein 600 1.8632 2.0956 0.5105 1.5160 
 
Genes not tested in secondary screen are highlighted in gray
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Table 2-2:  Secondary Screen Results 
 
Gene Symbol Full Gene Name 
Secondary 
Validation 
SREBF2 
sterol regulatory element binding transcription 
factor 2 ANDV specific 
CES2 carboxylesterase 2 (intestine, liver) ANDV specific 
HSPA2 heat shock 70kDa protein 2 ANDV specific 
IQGAP3 IQ motif containing GTPase activating protein 3 ANDV specific 
LGR6 
leucine-rich repeat containing G protein-coupled 
receptor 6 ANDV specific 
MCAT malonyl CoA:ACP acyltransferase (mitochondrial) ANDV specific 
NAP1L4 nucleosome assembly protein 1-like 4 ANDV specific 
PTGS2 
prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and 
cyclooxygenase) ANDV specific 
ST3GAL2 ST3 beta-galactoside alpha-2,3-sialyltransferase 2 ANDV specific 
ACSL6 acyl-CoA synthetase long-chain family member 6 ANDV and VSV 
AKR1C4 
aldo-keto reductase family 1, member C4 
(chlordecone reductase; 3-alpha hydroxysteroid 
dehydrogenase, type I; dihydrodiol 
dehydrogenase 4) ANDV and VSV 
ANKK1 ankyrin repeat and kinase domain containing 1 ANDV and VSV 
CLSTN3 calsyntenin 3 ANDV and VSV 
CPN1 carboxypeptidase N, polypeptide 1 ANDV and VSV 
DNPEP aspartyl aminopeptidase ANDV and VSV 
EVI1 ecotropic viral integration site 1 ANDV and VSV 
GALNT10 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 10 (GalNAc-
T10) ANDV and VSV 
IKZF4 IKAROS family zinc finger 4 (Eos) ANDV and VSV 
JARID1C jumonji, AT rich interactive domain 1C ANDV and VSV 
LHX1 LIM homeobox 1 ANDV and VSV 
LILRA2 
leukocyte immunoglobulin-like receptor, subfamily 
A (with TM domain), member 2 ANDV and VSV 
ORM1 orosomucoid 1 ANDV and VSV 
OXSR1 oxidative-stress responsive 1 ANDV and VSV 
PRPF8 
PRP8 pre-mRNA processing factor 8 homolog (S. 
cerevisiae) ANDV and VSV 
PSMC4 
proteasome (prosome, macropain) 26S subunit, 
ATPase, 4 ANDV and VSV 
PTGES prostaglandin E synthase ANDV and VSV 
QPCT glutaminyl-peptide cyclotransferase ANDV and VSV 
RCN3 reticulocalbin 3, EF-hand calcium binding domain ANDV and VSV 
SIRT2 
sirtuin (silent mating type information regulation 2 
homolog) 2 (S. cerevisiae) ANDV and VSV 
SNRPB 
small nuclear ribonucleoprotein polypeptides B 
and B1 ANDV and VSV 
SNRPD3 
small nuclear ribonucleoprotein D3 polypeptide 
18kDa ANDV and VSV 
VWA1 von Willebrand factor A domain containing 1 ANDV and VSV 
ZNF81 zinc finger protein 81 ANDV and VSV 
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PLA2G2F phospholipase A2, group IIF VSV specific 
PMPCB peptidase (mitochondrial processing) beta VSV specific 
RBM8A RNA binding motif protein 8A VSV specific 
VPS16 
vacuolar protein sorting 16 homolog (S. 
cerevisiae) VSV specific 
AANAT arylalkylamine N-acetyltransferase did not validate 
AMFR autocrine motility factor receptor did not validate 
ANAPC10 anaphase promoting complex subunit 10 did not validate 
ATP6V1D 
ATPase, H+ transporting, lysosomal 34kDa, V1 
subunit D did not validate 
CABP7 calcium binding protein 7 did not validate 
CASP7 caspase 7, apoptosis-related cysteine peptidase did not validate 
CCL16 chemokine (C-C motif) ligand 16 did not validate 
CCT8 chaperonin containing TCP1, subunit 8 (theta) did not validate 
CKM creatine kinase, muscle did not validate 
CLK4 CDC-like kinase 4 did not validate 
COX7B cytochrome c oxidase subunit VIIb did not validate 
DUSP14 dual specificity phosphatase 14 did not validate 
FGB fibrinogen beta chain did not validate 
FXYD3 FXYD domain containing ion transport regulator 3 did not validate 
GPR1 G protein-coupled receptor 1 did not validate 
GPR158 G protein-coupled receptor 158 did not validate 
GSTM4 glutathione S-transferase mu 4 did not validate 
HDAC7 histone deacetylase 7 did not validate 
HIATL1 hippocampus abundant transcript-like 1 did not validate 
HRH2 histamine receptor H2 did not validate 
HS3ST1 
heparan sulfate (glucosamine) 3-O-
sulfotransferase 1 did not validate 
INPP5F inositol polyphosphate-5-phosphatase F did not validate 
KCNK3 potassium channel, subfamily K, member 3 did not validate 
NAA20 
N(alpha)-acetyltransferase 20, NatB catalytic 
subunit did not validate 
NDUFA10 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 10, 42kDa did not validate 
NEUROD4 neurogenic differentiation 4 did not validate 
NUDT3 
nudix (nucleoside diphosphate linked moiety X)-
type motif 3 did not validate 
PELO pelota homolog (Drosophila) did not validate 
PHF15 PHD finger protein 15 did not validate 
PHF19 PHD finger protein 19 did not validate 
POLA1 
polymerase (DNA directed), alpha 1, catalytic 
subunit did not validate 
PPA1 pyrophosphatase (inorganic) 1 did not validate 
PRKCD protein kinase C, delta did not validate 
RASL12 RAS-like, family 12 did not validate 
SAG S-antigen; retina and pineal gland (arrestin) did not validate 
SAP18 Sin3A-associated protein, 18kDa did not validate 
SIN3B SIN3 homolog B, transcription regulator (yeast) did not validate 
SLC16A6 
solute carrier family 16, member 6 
(monocarboxylic acid transporter 7) did not validate 
SLC25A30 solute carrier family 25, member 30 did not validate 
45 
SLC2A2 
solute carrier family 2 (facilitated glucose 
transporter), member 2 did not validate 
SNW1 SNW domain containing 1 did not validate 
SORBS3 sorbin and SH3 domain containing 3 did not validate 
SRM spermidine synthase did not validate 
SWAP70 SWAP switching B-cell complex 70kDa subunit did not validate 
TEAD3 TEA domain family member 3 did not validate 
THY1 Thy-1 cell surface antigen did not validate 
TLR9 toll-like receptor 9 did not validate 
TNFRSF10B 
tumor necrosis factor receptor superfamily, 
member 10b did not validate 
TNNI3 troponin I type 3 (cardiac) did not validate 
TPX2 
TPX2, microtubule-associated, homolog (Xenopus 
laevis) did not validate 
UBE2V2 ubiquitin-conjugating enzyme E2 variant 2 did not validate 
UBR2 
ubiquitin protein ligase E3 component n-recognin 
2 did not validate 
UQCR10 
ubiquinol-cytochrome c reductase, complex III 
subunit X did not validate 
VIL1 villin 1 did not validate 
WFDC5 WAP four-disulfide core domain 5 did not validate 
ZIC5 Zic family member 5 did not validate 
ZNF462 zinc finger protein 462 did not validate 
ZNF496 zinc finger protein 496 did not validate 
ZNF676 zinc finger protein 676 did not validate 
46 
To infect cells, we utilized a VSV construct similar to the VSV∆G*rLuc construct 
described above, except the rLuc gene was replaced with Red Fluorescent Protein 
(VSV∆G*RFP) making it possible to detect infected cells by flow cytometry or 
fluorescent microscopy.  After confirming SREBF2 knockdown, we infected SREBF2 
siRNA-treated 293T cells with ANDV-VSV∆G*RFP and quantified virus infection by 
both flow cytometry for RFP expression and western blot against VSV-M protein.  As a 
control, we also infected cells with VSV-G-VSV∆G*RFP pseudovirions.  Relative to 
non-targeting control siRNA, infection was inhibited ~2-fold by two different siRNAs 
targeting SREBF2 as measured by percent RFP positive cells. Infection with VSV-G-
VSV∆G*RFP was unaffected, suggesting this effect is due to the ANDV-glycoprotein 
and not post-entry effects on VSV replication (Figure 2-4B). 
To determine the specificity of this effect within the Bunyaviridae family, these 
experiments were extended to other Hantaviruses including Hantaan (HTNV), Puumala 
(PUUV), and Sin Nombre Virus (SNV) -VSV∆G*RFP pseudotypes.  Infection by the 
more distantly related HTNV and PUUV constructs was found to be uninhibited by 
SREBF2 knockdown.  For the more closely related SNV, infection was inhibited to 
nearly the same degree as ANDV, but by only one of two individual siRNAs (Figure 2-
4B)).  This suggests that the role SREBF2 plays in infection may be specific to New 
World Hantaviruses.  
Given the role of cholesterol uptake pathway genes in ANDV infection, we 
attempted to determine the effect of cholesterol depletion on infection.  MβCD is a small 
molecule capable of binding and extracting cholesterol from cell membranes (Kilsdonk et 
al., 1995).  293T cells were pre-treated with MβCD or no drug prior to infection with  
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Figure 2-4:  Effect of SREBF2 knockdown on Hantavirus Infection.
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GAPDH was used as a loading control.  (B) 293T/17 cells were reverse-transfected with 
SREBF2 si-1 and si-2.  Cells were incubated 72hrs to allow for protein knockdown.  
Cells were infected with VSV∆G*RFP pseudotypes bearing the glycoproteins of the 
Hantaviruses indicated.  Cells were also infected with another Bunyavirus - MP12, a 
vaccine strain of RVFV. VSV-G-VSV∆G*RFP was included as a control.  Infection was 
measured by flow cytometry for RFP expression or staining for MP12 nucleocapsid.  
Data is presented as percent infection relative to negative control siRNA (mean ± SEM, 
n≤3).  *p<0.01 unpaired, two-tailed T-test. 
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infected in the presence or absence of drug with the indicated Hantavirus pseudotype on a 
VSV∆G*RFP core.  VSV-G-VSV∆G*RFP was used as a negative control for a virus 
unaffected by cholesterol perturbation.  Infection was measured as %RFP-positive by 
flow cytometry.  Data is presented on a log10 scale as percent infection relative to no 
drug control (mean ± SEM, n≥4). (B) Pretreatment of cells with methyl-β-cyclodextrin 
(MβCD) inhibits the infection of Vero E6 cells with wildtype Andes virus. Cells 
pretreated with 2.5 mM drug or vehicle (DMEM) were infected with wild type ANDV in 
the presence of drug.  Cells were collected 72 hours post infection and quantified by flow 
cytometric analysis. Cells were immunostained for ANDV N.  Infectivity has been 
normalized relative to untreated control cells. Error bars are SEM (n=3).  Wild-type 
ANDV experiments performed by Emily Bruce and Amber Riblett. 
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ANDV, HTNV, PUUV, SNV, and VSV-G -VSV∆G*RFP pseudotypes for 1 hour in the 
presence or absence of drug.  MP12 was also tested in the same manner.  Drug and virus 
were then removed and replaced with normal media.  Decreased cholesterol levels were 
confirmed by a fluorometric cholesterol content assay.  For VSV, there was no significant  
inhibition of infection by MβCD compared to untreated cells.   For ANDV and SNV 
pseudotypes, however, infection was inhibited  ~30 and ~60-fold, respectively.  For  
HTNV and PUUV pseudotypes, however, infection was inhibited ~10-fold compared to 
untreated cells (Figure 2-5A). 
Although confident that the pseudotype data was representative of the actual 
virus, we attempted to confirm these findings with live, wild-type ANDV under BSL-3 
conditions.  Our current assays are only able to detect ANDV infection in Vero cells, 
which are derived from African Green Monkey kidney epithelial cells.  Because of this, 
we were unable to test the effects of SREBF2 siRNA knockdown on live ANDV 
infection; however, we were able to test the effects of MβCD.  Cells were pre-treated 
with MβCD for 1hr prior to infection, infected with wild-type ANDV for 2hr after which 
the virus inoculums was removed.  Four days post-infection, cells were stained with an 
anti-ANDV nucleocapsid antibody and percent of cells infected measured by flow 
cytometry.  Infection with ANDV was decreased ~100-fold in MβCD-treated cells 
compared to untreated cells.  VSV infection of VERO cells remained unaffected by 
MβCD treatment, as expected (2-5B).  These results confirm not only that ANDV 
infection is cholesterol-dependent, but also that our Hantavirus pseudotypes are indeed 
representative of their wild-type counterparts. 
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We also attempted to use the SREBF2-specific small molecule inhibitors betulin 
and fatostatin to demonstrate the effects of SREBF2 perturbation on ANDV infection.  
These drugs interact with SCAP to prevent the ER-to-Golgi translocation required for 
SREBF2 activation.  These drugs would be particularly useful in live ANDV experiments 
given the limitation to work only in non-human VERO cells.  Studies with these drugs 
using ANDV-VSV∆G*RFP pseudotypes showed no effects on infection, however, 
studies on their effects on cholesterol likewise showed no decrease in cholesterol content 
rendering these experiments inconclusive.   Further assays will need to be developed to 
confirm effects of these drugs on SREBF2 itself. 
 At the same time that we identified SREBF2, the Bates lab at the University of 
Pennsylvania was using a replication-competent ANDV-VSV pseudotype nearly identical 
to that used in our siRNA screen.  Using that virus in a retroviral mutagenesis screen in a 
human haploid cell line (Hap1), they identified the 4 members of the cholesterol uptake 
regulation pathway, including SREBF2 and the 3 members of its regulation cascade 
(SCAP, S1P, and S2P).  Indeed, identification of this pathway by another independent 
method was a major impetus for our follow-up of SREBF2 from our screen.  It should be 
noted that although S1P and S2P were present in the screened siRNA library, these were 
not identified as hits.  The reasons for this are unclear but are could have been due to 
insufficient protein knockdown.  In fact, follow-up experiments using siRNA to 
individually knockdown SCAP, S1P, and S2P were unable to demonstrate clear 
knockdown of these proteins or inhibition of infection. 
 Further studies of this pathway and its effects on Hantavirus infection were 
performed in collaboration by the Bates and Doms labs.  In addition to the data for 
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SREBF2 presented above, it was demonstrated that mutant Chinese Hamster Ovary 
(CHO) cells lacking SCAP, S1P, or S2P were significantly impaired in their ability to 
support ANDV entry, a greater than 10-fold defect compared to wild-type CHO cells 
(Figure 2-6).  Furthermore, use of the S1P-specific small molecule inhibitor PF-429242 
inhibited wild-type ANDV infection in Vero E6 cells more than 10-fold compared to 
untreated cells (Figure 2-7).  PF-429242 also inhibited infection by recombinant ANDV-
VSV in the human A549 lung epithelial cell line (data not shown). 
In order to determine the mechanism of inhibition of ANDV infection, binding 
and internalization studies of recombinant virus were performed comparing wild-type 
(WT) and S1P-knockout Hap1 cells.  Recombinant VSV pseudotypes bearing ANDV and 
VSV glycoproteins were bound to cells and internalization of virions was quantified by 
qPCR (Figure 2-8B).  Results from these experiments identified no defect in binding of 
virions to WT or S1P-null Hap1 cells.  However, there was a 10-fold reduction in 
internalization of ANDV, but not VSV pseudovirions.  This 10-fold reduction in 
internalization corresponds with the 10-fold reduction seen for infection of S1P-null cells 
compared to WT cells (Figure 2-8A).  These results demonstrate that inhibition of ANDV 
entry is secondary to a defect in endocytosis rather than a defect in binding. 
 
 
 
 
 
 
 Figure 2-6: Infection of Chinese Hamster Ovary (CHO) cells null for S1P, S2P, or 
SCAP. CHO cells were infected 
VSV∆G*RFP (rVSV-ANDV). Infections 
indirect immunostaining . Infectivity has been normalized relative to wild type (CHO
K1) cells.  Error bars are SEM (n=3).
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Figure 2-8: Quantitative PCR analysis of viral RNA during infection of human cells.
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was measured by warming cells to 37°C for one hour to allow endocytosis before 
treatment with trypsin to remove non-interalized virus.  Cells were then washed and 
collected.  Cell pellets and virions were lysed for RNA extraction and viral RNA (vRNA) 
levels were measured by qRT-PCR. Viral RNA values were normalized to GAPDH RNA 
levels to control for input RNA levels and plotted relative to virus bound to HAP1WT 
cells.  The mean and standard error (6 replicates from 3 independent experiments) are 
plotted.  (C) Infectivity of HAP1WT and HAP1S1P cells. HAP1WT or HAP1S1P cells were 
infected with the VSV-G or rVSV-ANDV expressing RFP.  12 hours post-infection, cells 
were and analyzed by flow cytometry for RFP expression.  Infection was normalized to 
infection levels in HAP1WT cells.  The mean and standard error (7 replicates from 5 
independent experiments) are plotted.   Experiment performed by Amber Riblett. 
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Discussion 
We optimized and employed a high-throughput siRNA screen in a human cell line 
to identify novel host factors for the entry of representative Hantavirus, ANDV.  We 
ultimately identified 9 genes that may play a role in ANDV entry.  Among them was 
SREBF2, an important transcriptional regulator of the cholesterol uptake pathway.  At the 
same time we identified these hits, a retroviral mutagenesis screen in human haploid cells 
identified 4 members of the cholesterol uptake regulation pathway – SREBF2 and three 
members of its regulation cascade (SCAP, S1P, and S2P).  Based on this, we focused 
follow-up efforts on identifying the role of SREBF2 and this pathway on ANDV entry.  
Further experiments on the remaining 8 genes identified in our screen will need to be 
performed to identify what role, if any, they play in Hantavirus entry. 
Since two independent screens in different experimental systems both identified 
the same gene, we were confident that we had identified a pathway required for ANDV 
infection.  By using a VSV-ANDV pseudotype system and subsequently controlling for 
effects on replication of the VSV core, we were able to immediately attribute the defect 
in infection to effects on ANDV glycoprotein-mediated entry.  To our knowledge, this is 
the first example of the use of two independent genetic screens used to simultaneously 
identify a host factor required for virus infection.  Further analysis and follow-up of the 
genes identified in both screens may still identify other genes or pathways that play a role 
in ANDV entry. 
The importance of cholesterol is commonly related to its role in the formation of 
lipid rafts.  Lipid rafts are cholesterol- and sphingolipid-rich microdomains of the plasma 
membrane known to be involved in a number of biological processes including signaling, 
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endocytosis, and trafficking.  Lipid rafts have been shown to play an important role in the 
replication cycle of many viruses, from entry through to assembly and budding (Chazal & 
Gerlier, 2003).  
Lipid rafts are also required for caveolin-mediated endocytosis – a pathway often 
used by viruses for entry and trafficking to endosomal compartments for entry (Mercer, 
Schelhaas, & Helenius, 2010).  Caveolin proteins cluster at lipid rafts in the plasma 
membrane to form flask-shaped invaginations and cause eventual budding of 
compartments, known as caveosomes, in a dynamin-dependent process.  
Our binding and internalization studies comparing wild-type and S1P-knockout 
Hap1 cells localized the inhibition of ANDV entry to a defect in endocytosis rather than a 
defect in binding.  There are multiple potential explanations for this.  The first is that 
caveolin-mediated endocytosis is non-functional in these cells.  Thus far, the specific 
endocytic pathway that ANDV utilizes has not been established.  Previous studies of 
Hantavirus entry using drug inhibitors have suggested that HTNV enters via clathrin-
mediated endocytosis while ANDV entry is uninhibited by perturbations of clathrin or 
caveolin (Jin et al., 2002; Rojek et al., 2008).  Given only a small number of studies, it is 
difficult to definitively say which, if any, pathway is preferentially utilized by 
Hantaviruses.   
Our data demonstrates that Hantaviruses are susceptible to MβCD depletion of 
cholesterol.  Studies of caveolin-mediated endocytosis commonly use MβCD as a 
molecular inhibitor of this pathway, but as a general cholesterol-depleting agent, it is not 
completely specific for only caveolin.  Further experiments using caveolin dominant-
negatives, caveolin-specific siRNAs, and caveolin co-localization by 
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immunofluorescence will be required to definitively determine the role of caveolin in 
ANDV entry. 
Another explanation for a defect in endocytosis could be that host factors required 
for entry, specifically attachment factors and receptors, become mis-localized or are 
unable to signal in the absence of lipid rafts.  The difference in density of lipid rafts 
compared to the surrounding plasma membrane allows for the inclusion and exclusion of 
membrane proteins.  This clustering is required for the interaction of some proteins.  
ANDV would still be able to bind its receptor(s) but the receptor may be unable to 
interact with specific signaling partners for uptake. 
There have been two previously identified Hantavirus entry factors – β3 integrin 
and Decay-Accelerating Factor (DAF) (Gavrilovskaya et al., 1999; Gavrilovskaya et al., 
1998; Krautkrämer & Zeier, 2008; Matthys et al., 2010).  The exact mechanism by which 
these molecules mediate entry is unclear; however, it is known that both of these 
molecules localize to lipid rafts.  Previous data from our lab demonstrated that Hantavirus 
(HTNV and PUUV) entry does not correlate with β3 integrin expression across multiple 
cell lines perhaps suggesting that other proteins mediate could mediate ANDV infection.  
However, studies from other labs have shown β3 integrin is sufficient to render non-
permissive CHO cells permissive to infection.   
PF-429242, an S1P-specific small molecule inhibitor, inhibited infection of 
several hantavirus pseudotypes; however, inhibition of two New World Hantaviruses, 
ANDV and SNV, was greater than the inhibition of an Old World Virus, HTNV.  
Similarly, siRNAs targeting SREBF2 had significant effects on New World Hantaviruses, 
ANDV and SNV, but no effect on Old World Hantaviruses, HTNV and PUUV.  This 
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data could suggest that while cholesterol and lipid rafts are important for several 
hantaviruses, some are more sensitive to cholesterol perturbations than others.  This may 
indicate differences in receptor usage or the mechanisms by which Old and New World 
Viruses enter cells. 
Part of the goal of identifying host factors important for ANDV is eventually to 
identify potential therapeutic targets.  In this study we have used a number of drug 
inhibitors to inhibit infection using in vitro models of infection.  Our results demonstrate 
that presently available small molecule cholesterol inhibitors are capable of inhibiting 
ANDV infection.  Fortunately, many of these drugs have already been approved for use 
in humans and may be useful as drugs for treatment of Hantavirus infection.  These drugs 
have also been studied for safety and efficacy in mice and could be amenable to assessing 
their therapeutic potential in an in vivo model of ANDV infection in Syrian hamsters.  
The feasibility of this approach will ultimately depend on the exact mechanism for 
Hantavirus cholesterol-dependence. 
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Materials and Methods 
Virus Pseudotype Production.  293T/17 cells were maintained in DMEM, 10% 
FBS, 1% PenStrep at 37°C at 5% CO2.  One day prior to transfection, 293T/17 were 
plated for  ~70% confluence.  The following day, cells were transfected with the 
Hantavirus glycoprotein of interest in the pWRG or pCAGGS expression vector (ANDV-
M-pWRG, HTNV-M-pWRG, SNV-M-pCAGGS, PUUV-M-pCAGGS, VSV-G-
pCAGGS) using Lipofectamine 2000 transfection reagent according to the 
manufacturer’s protocol.  18 hours post-transfection, cells were transduced with VSV-G-
VSV∆G*rLuc or VSV-G-VSV∆G *RFP at a MOI of ~2.5 for 1hr at 37°C.  The VSV-G-
VSV∆G*rLuc or *RFP inoculum was removed and replaced with DMEM, 10%FBS, 
1%PenStrep and the cells were incubated until significant CPE was detected, at 
approximately 2 days post-transduction.  Supernatant containing virus was clarified by 
spinning at 1500 rpm for 10min and put through a 0.45µm filter to clear cellular debris.  
Tris/HCl pH8.0 was added for a final concentration of 25mM and virus was aliquoted 
and stored at -80°C.  For VSV∆G*rLuc pseudovirions, virus preps were titered to give 
RLUs within the linear range of the assay. For RFP experiments, virus was titrated on 
Vero E6 cells and infection was measured by flow cytometry to estimate infectious 
units/mL. 
293T-ffLuc cell line.  The 293T-ffLuc cell line was created by stable transfection 
of HEK293T/17 cells with the pGL4.27[luc2P/minP/Hygro] Vector (Promega) 
expressing firefly luciferase and a Hygromycin B selectable marker.  293T/17 cells were 
maintained in DMEM, 10% FBS, 1% PenStrep at 37°C and 5% CO2.  One day prior to 
transfection, 293T/17 cells were plated in a six-well format for 70% confluence.  The 
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following day, the cells were transfected using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s protocol.  After six hours, the transfection media was 
removed and replaced with DMEM, 10% FBS, 1% PenStrep.  At 24hrs post-transfection, 
transfected and untransfected control cells were placed under Hygromycin B (Invitrogen) 
selection at 200µg/mL, a concentration determined empirically specifically for selection 
of 293T/17 cells in our hands.  Approximately 14 days post-transfection, single colonies 
were visible in transfected wells, but not in untransfected control wells.  Several of these 
colonies were harvested, grown, and tested for firefly luciferase expression using the 
Bright-Glo Luciferase system (Promega) according to manufacturer’s protocol.  The 
clone with the highest level of expression was chosen for further experiments. 
siRNA controls.  The AllStars Negative Control siRNA (Qiagen) was used a 
non-targeting control.  The AllStars Hs Cell Death siRNA (Qiagen), which induces cell 
death via knockdown of a proprietary cellular target, was used as positive control for 
convenient visualization of effective siRNA transfection.  The siRNA sequence targeting 
Firefly Luciferase expression from the luc2P gene of the pGL4.27 vector (Ambion) was 
obtained from Ambion technical support via personal communication and was custom 
synthesized for our experiments (sequence: GGACGAGGACGAGCACUUCUU).  The 
siRNA targeting Renilla Luciferase expression was a pool of two siRNAs obtained from 
Dharmacon using their custom siRNA generation algorithm (sequences: 
GAUCAAAUCUGAAGAAGGAUU, CGUGAAAUCCCGUUAGUAAUU).  The 
siRNA targeting ATP6V0C was the ON-TARGETplus pooled ATP6V0C siRNA from 
Dharmacon (sequences: CCAGCUAUCUAUAACCUUA, 
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CCCGACUAUUCGUGGGCAU, GCUCUGUGUAUGCGGAUGA, 
GGCACAGCCAAGAGCGGUA). 
siRNA Screen.  siRNAs from the Ambion Druggable genome library 
representing 9,102 genes were spotted in 54 384-well white bottom plates.  siRNAs were 
arrayed in a 2x2 format such that each gene was targeted by 2 different pools of 2 
siRNAs - 4 unique siRNAs in total.  Each of the positive and negative control siRNAs 
described above were added by hand into triplicate wells on each plate (2µL of 0.8µM 
solution).  Using a liquid handler (WellMate, Thermo Fisher) to decrease variability, 
0.5µL of HiPerFect (Qiagen) in 9.5µL of OptiMem (Gibco) was added to each well and 
incubated for 15min at room temperature to allow complex formation. 2400 293T-ffLuc 
cells in 30µL of DMEM, 10% FBS, 1%PenStrep were plated per well on top of the 
complexes for a 40nM final siRNA concentration in 40µL total volume.  Plates were 
incubated for 72hrs and then infected with ANDV-VSV∆G*rLuc.  24hrs post-infection, 
Firefly Luciferase expression was measured using 20µL of a mixture of Bright Glo 
Luciferase diluted 1:1 with PBS.  Subsequently, Renilla Luciferase expression was 
measured using 20µL of the Stop&Glo Reagent component of the Dual Glo Luciferase 
System (Promega).  Luciferase expression was measured as Relative Light Units (RLUs).  
Robust z-scores were calculated for each plate using the median and interquartile ranges 
of log-transformed RLUs [(log(sample RLU) – log(median RLU))/IQR * 0.74] for both 
infection (Renilla Luciferase) and cell viability (Firefly Luciferase). 
For the secondary screen, 96 genes identified in the primary screen were selected 
for secondary validation.  Three unique siRNAs for each gene, different from those used 
in the primary screen, were obtained from Ambion and arrayed in white-bottom 96-well 
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plates by hand (2µL of 2µM siRNA).  The positive and negative controls described above 
were also plated in triplicate wells.  The same protocol was used for the secondary as in 
the primary screen, but volumes were scaled up 2.5-fold for a 100µL final volume in the 
96-well format.  1.25µL of HiPerfect in 23.75µL of OptiMem were added to each well 
and incubated for 15min at room temperature to allow complex formation.  1x104 293T-
ffLuc cells per well in 75µL of DMEM, 10% FBS, 1% PenStrep were plated on top of the 
complexes for a 40nM final siRNA concentration.  Plates were incubated for 72hours.  
Cells were infected with ANDV-VSV∆G*rLuc at a dilution within the linear range of the 
assay.  24 hours posted infection, firefly luciferase expression was measured using 50µL 
of a mixture of Bright Glo Luciferase diluted 1:1 in PBS.  Subsequently, Renilla 
Luciferase expression was measured using 50µL of the Stop&Glo Reagent component of 
the Dual Glo Luciferase System.  Robust z-scores of log-transformed infection RLUs 
normalized to cell viability RLU were calculated [(log(sample infection RLU/cell 
viability RLU) - log(median infection RLU/viability RLU))/IQR * 0.74]. 
Western Blot.  293T cells were lysed using 1% Triton-X 100 lysis buffer (50mM 
Tris, 150mM NaCl, 5mM EDTA) with protease inhibitors (Roche) for 10min at 4°C.  
The membrane debris was cleared by high speed microcentrifuge spin at 13000rpm for 
10min at 4°C and the supernatants were collected.  The lysates were reduced using 
NuPAGE® LDS Sample Buffer and Reducing Agent (DTT) (Invitrogen) and incubating 
at 95°C for 10min.  The reduced lysates were run on a SDS-PAGE 4-12% Bis-Tris gel 
for 1hr at 150V and transferred to a polyvinylidene fluoride membrane for 45min at 24V.  
Membranes were blocked for 1hr in 5% non-fat dry milk in PBS with 0.1% Tween-20.  
Membranes were then probed with the specified antibody for 1hr at room temperature or 
66 
overnight at 4°C.  HRP activity was visualized by ECL (ThermoScientific, SuperSignal 
West Femto).  Anti-SREBF2 mouse monoclonal antibody was obtained from Millipore 
(clone 2545).  Anti-GAPDH mouse monoclonal antibody was obtained from Calbiochem 
(clone 6C5). Anti-mouse HRP-conjugated antibody was obtained from Jackson Lab. 
SREBF2 knockdown infections.  The siRNAs targeting SREBF2 were obtained 
from Ambion (s27, GCGCUCUCAUUUUACCAAATT) and Qiagen (SI00065856, 
GCAGUGUCCUGUCAUUCGATT) and are referred to as SREBF2 si-1 and SREBF2 si-
2, respectively.  These siRNAs were plated in a 12-well format (20µL of 2µM siRNA) 
and complexed with 12.5µL of HiPerFect in 238.5µL OptiMem.  7.5x104 293T/17 cells 
were plated onto the  siRNA complexes in 750µL volume giving a 40nM final siRNA 
concentration in 100µL final volume.  The cells were incubated for 72hrs to allow for 
knockdown.  Cells were then infected with VSV∆G*RFP pseudovirions pseudotyped 
with ANDV, HTNV, PUUV, SNV, or VSV glycoproteins (MOI ~0.1) or MP12 (MOI 
~0.5).  18hrs post-infection, cells were fixed in 1% paraformaldehyde in FACS buffer 
(PBS-/-, 2.5% FBS, 2mM EDTA).  Infection was measured as percent RFP-positive RFP 
expression by flow cytometry on a BD LSR II.  At the same time, duplicate wells for 
each condition were plated and collected for western blot (see above) to confirm SREBF2 
protein knockdown.  
MβCD inhibition of pseudotype infection.  One day prior to infection, 293T 
cells were plated at 4x105 cells/well in 12-well format.  The following day, cells were 
pre-treated with no drug or 2.5mM MβCD in DMEM, 10% FBS, 1% PenStrep for 45min 
and then infected with ANDV-, HTNV-, PUUV-, SNV-, or VSV-G-VSV∆G*RFP (MOI 
~0.1) for 1hr in the presence of 2.5mM MβCD or no drug.  After 1hr, virus and drug were 
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removed and replaced with DMEM, 10% FBS, 1% PenStrep.  At 24hrs post-infection, 
cells were fixed and measured by flow cytometry as described above.  
SCAP, S1P, and S2P-null CHO mutant cell lines:  CHO cell lines null for S1P, 
SCAP (a kind gift of Michael Brown and Joseph Goldstein, University Texas 
Southwestern, (Hua et al., 1996; Sakai et al., 1996), and S2P (a kind gift of TY Chang, 
Dartmouth Medical School (Sakai et al., 1996)) were maintained in a 1:1 mixture of 
Ham's F12:DMEM supplemented with 10% FBS, penicillin, streptomycin, 5 µg/ml 
cholesterol (Sigma), 50 µM sodium mevalonate, and 20 µM sodium oleate at 37°C, 5% 
CO2. CHO cells were regularly selected with 50 µg/ml Amphotericin B (Sigma) as 
previously described (Sakai, Duncan et al. 1996).  
Small molecule inhibition of wildtype ANDV.  Wildtype ANDV (Chilean strain 
9717869) was obtained courtesy of Dr. Connie Schmaljohn at the U.S. Army Medical 
Research Institute of Infectious Diseases. All infections with wildtype ANDV were 
performed using institution-approved biosafety level 3 (BSL3) containment procedures. 
All experiments with live ANDV were performed using Vero E6 cells maintained with 
DMEM, 10% FBS, 1% PenStrep at 37°C, 5% CO2.  For PF-429242 studies, cells were 
pretreated with the indicated concentrations of PF-429242 (Tocris Biosciences) in DMSO 
for 24 h before infection.  All infections and overlays were carried out in the continued 
presence of drug or DMSO, for the length of the infection.  Cells were pretreated with 
MβCD (Sigma-Aldrich, 128446-36-6) for one hour prior to infection. Cells were infected 
with ANDV at an MOI of 3 for two hours at 37°C.  Viral inoculum was removed, cells 
were overlaid with fresh media, and media (containing drug or DMSO where indicated) 
was replaced daily.  Cells were harvested for flow cytometry three to four days post-
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infection and fixed for one hour in 4% formaldehyde.  Cells were permeabilized and 
stained with rat anti-ANDV N sera (1:300, courtesy of Dr. Andrew Pekosz, (Rowe, 
Suszko, & Pekosz, 2008) and a fluorescently-conjugated secondary antibody (1:1000, 
anti-Rat 647 Invitrogen A-21247).  Infected cells were quantified using a LSR flow 
cytometer (BD Biosciences) and 105 events were collected in triplicate.  
Binding and Internalization Assay.  HAP1 cells, a derivative of the human 
myeloid leukemia cell line, KBM7 (Carette, Raaben et al. 2011), were maintained at 
37°C, 5% CO2 in Iscove's Modified Dulbecco's Medium (IMDM), 10% FBS, 1% 
PenStrep (Invitrogen). HAP1 cells were seeded in 24 well plates in IMDM containing 
10% FBS. 16 hours later media was replaced with IMDM containing a 1:8 ratio of 10% 
FBS to delipidated FBS (created through Cab-O-Sil treatment, Cabot Corporation, 
(Weinstein 1979)).   24 hours later the binding and internalization assay was performed.  
Cells were pre-chilled on ice at 4°C while rocking, rinsed with ice-cold PBS and 
incubated with rVSV-ANDV for one hour on ice.  Samples were washed with ice-cold 
PBS to remove unbound virus, samples to measure bound virus were collected by 
scraping cells into PBS, followed by additional washing.  Samples to measure 
background were washed with PBS and treated with 0.05% Trypsin-EDTA (Gibco) for 
ten minutes at 37°C.  Cells were added to media containing FCS to quench trypsin 
activity and washed with PBS.  Samples to measure internalized virus were washed with 
PBS and incubated in warm IMDM containing delipidated media (as referenced above) at 
37°C for one hour to allow endocytosis.  After the one-hour warming period, cells were 
washed with PBS and treated with 0.05% trypsin for ten minutes at 37°C.  Cells were 
then added to media containing FCS and washed with PBS.  Samples were kept on ice 
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after the final washing step, and lysed according to the QIAGEN RNeasy Mini kit.  Total 
RNA from cells was isolated using the QIAGEN RNeasy Mini kit according to the 
manufacturer's protocol.  RNA was quantified by measuring absorbance at 260 nm.  
First-strand cDNA was generated from 1 µg of total RNA using the SuperScript VILO 
cDNA Synthesis Kit (Invitrogen) according to manufacturer's protocol.  Primers specific 
to the VSV N segment (Supplemental Information) were used for RT-PCR. Each reaction 
was then performed using an ABI 7500 real-time PCR system (Applied Biosystems) with 
the following conditions: (i) denaturation at 95°C for 20 sec; and (ii) 40 cycles of PCR 
amplification, with denaturation at 95°C for 3 sec and annealing and extension at 60°C 
for 30 sec.  Data were analyzed using the ∆∆CT method (Livak & Schmittgen, 2001)  by 
calculating the change in gene expression normalized to that of GAPDH as a 
housekeeping gene. 
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Abstract 
The specific mechanisms of Hantavirus entry are unclear.  Although some host 
proteins, such as DAF and β3 integrin, have been implicated in Hantavirus entry, their 
exact roles are not well-defined.  We attempted to identify novel host factors important 
for entry using a comparative genomics analysis approach. We hypothesized that the 
permissiveness to infection for a given cell line correlates with the expression of host 
factors that mediate infection.  Using the NCI60 panel of highly-characterized cell lines, 
we infected these cell lines with a Hantavirus-VSV pseudovirions and used publicly 
available microarray gene expression data for the NCI60 to correlate infection with 
expression levels of specific genes.   
We chose to focus on a single Hantavirus, ANDV for analysis and follow-up.  
Using VSV-G-VSV∆G as a control, we were able to rule out genes associated with VSV 
replication and focus on genes correlated specifically with ANDV glycoprotein-mediated 
entry.  We identified 70 genes that correlated specifically with ANDV entry.  Focusing 
on membrane or membrane-associated proteins as potential receptors or entry factors, we 
identified a list of 31 membrane genes.  Further analysis for genes that were not 
previously tested in our siRNA screen for host factors related to ANDV entry identified 
14 untested candidate membrane genes.  The transmembrane gene IGSF3 was identified 
as our most promising candidate, however, initial validation experiments using siRNA 
knockdown of IGSF3 in human cells demonstrated no effect on infection.  Furthermore, 
attempts at cDNA rescue for IGSF3 and 6 other candidate genes in a poorly-permissive 
CHO cell line also showed no effects on infection.  Although no genes have yet been 
validated, we have tested only a small number of potential genes and future experiments, 
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possibly using more high-throughput methods, will be required to test the remaining 
genes to definitively conclude if this approach represents a valid method to identify host 
factors for virus entry. 
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Introduction 
 Viruses are obligate intracellular pathogens and must subvert host cell functions 
to replicate.  This sort of misappropriation occurs at all steps of the virus life cycle 
including entry, replication, assembly, and exit.  For example, all viruses must utilize host 
ribosomal machinery to express viral proteins, often using mechanisms to inhibit host 
protein production to preferentially express their own.  In the case of entry, defined for 
our purposes as all steps from virus binding to uncoating of the viral genome, viruses 
commonly use specific host proteins and pathways to bypass cellular barriers to infection, 
including the plasma membrane itself.   
Generally, viruses use host surface proteins as attachment factors or receptors to 
bind to cells.  In some cases, this binding triggers mechanisms leading to fusion and 
release of the genome into the cell.  In addition, virus-receptor binding can induce 
signaling that leads to endocytosis of the virion and trafficking to subcellular 
compartments.  Host factors such as proteases or the low pH of endocytic compartments   
(maintained by the endosomal proteins) are then used as triggers for membrane fusion 
and uncoating.  In each case, the virus subverts normal host functions for its own 
purposes.  In some cases, as with the endocytic machinery, these host factors are 
constitutively expressed in nearly all cell types.  In contrast, expression of other factors 
such as virus receptors may be more limited and cell-type specific.  Viruses tend to 
preferentially infect specific cell types and the specific interactions between virus and 
host proteins determine this cellular tropism.  
 The expression level of a given gene in any cell type can be determined by a 
number of methods that analyze mRNA or protein levels in a cell.  Using cDNA 
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microarray technology, the levels of mRNA expression can be determined for thousands 
of genes at a single time.  This method uses microarray chips spotted with sequence-
specific probes to hybridize with fluorescently labeled cDNAs.  The fluorescence at a 
given probe can then be analyzed to determine mRNA levels, which often correlate with 
protein levels. This sort of data can be used for a number of purposes, for example, 
analyzing changes in gene expression in a cell under different conditions.  It could also be 
used to compare gene expression among different cell types or cell lines. 
 Given the need for viruses to interact with specific host proteins, the analysis of 
gene expression in preferentially infected cell types could identify important host genes 
for infection.  This method can generally be referred to as Comparative Genomics 
Analysis (CGA).  In this approach, the hypothesis is that differences between permissive 
and non-permissive cell lines, with respect to virus infection, are due to differential 
expression of host factors required for infection.  Alternatively, these differences could be 
due to differential expression of restrictive, anti-viral host factors.  In either case, 
identification of these genes can elucidate new aspects of the virus-host interaction.  
CGA has been successfully used to identify Ephrin B2 as the receptor for Nipah 
and Hendra Viruses and Nectin4 as an epithelial receptor for measles virus (Bonaparte et 
al., 2005; Mühlebach et al., 2011; Noyce et al., 2011).  These studies identified multiple 
cell lines that were either permissive or non-permissive to infection by their virus of 
interest.  cDNA microarray analysis was used to identify genes that were up-regulated in 
permissive cell lines relative to non-permissive cell lines.  Multiple genes were identified 
and further studies were able to identify which of those genes were important and what 
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role they played in virus entry.  We set out to use this approach to identify host factors 
important for Hantavirus entry. 
Because Hantaviruses are BSL-3 viruses in cell culture, our lab has utilized a 
Vesicular Stomatitis Virus (VSV) pseudotype system to study Hantavirus entry under 
BSL-2 conditions in which the gene encoding the native glycoprotein of VSV (VSV-G) 
has been replaced with a reporter gene, either Renilla Luciferase (rLuc) or red fluorescent 
protein (RFP), creating a replication incompetent construct referred to as VSV∆G*rLuc 
or VSV∆G*RFP.  The Hantavirus glycoprotein (M segment) is provided in trans to 
produce Hantavirus-VSV∆G*rLuc or *RFP pseudotypes.  Since these pseudotypes are 
only capable of a single round of infection, our assays measure the entry and replication 
required for reporter protein production.  Assembly and budding are not assessed.  To 
control for post-entry effects on replication, we also infected cells with pseudotypes 
bearing the native VSV-G, thereby allowing us to attribute differences to the Hantavirus 
glycoprotein. 
The use of CGA to identify host factors is dependent on the identification of cell 
lines with differences in permissivity to infection.  Previous studies in our lab used 
ANDV-, HTNV-, and PUUV-VSV∆G*rLuc pseudotypes to test 23 cell lines (11 for 
ANDV and 16 for HTNV and PUUV, with 4 overlapping) to examine the cellular 
tropism of these viruses (Higa et al., 2012; Ray et al., 2010).  These included human, dog, 
avian, rat, murine, and reptilian cell lines. Of these cell lines, only SupT1 and MOLT4, 
both of which are hematopoietic in origin, were identified as very poorly permissive to 
HTNV and PUUV entry (Higa et al., 2012).  Luciferase activity for HTNV and PUUV 
pseudotypes in these cells was ~100-fold less than their luciferase activity in Vero cells.  
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Meanwhile, luciferase activity for VSV pseudotypes remained virtually unchanged in 
these cell types compared to Vero cells, indicating a block at the level of entry.  
Unfortunately, these were the only cell lines identified with a significant entry defect, 
which limited future studies. 
The number of genetic differences between two given cell lines can number into 
the thousands.  In order to increase the likelihood of finding a specific genetic difference 
responsible for a phenotypic difference, it is preferable to use cell lines with similar 
genetic backgrounds.  Ideally, this would be a parental cell line and a phenotypically 
different but nearly identical derivative of that cell line.  In the absence of that, one might 
compare multiple cell lines of similar origin, for example, comparing a group of 
permissive epithelial cell lines to a group of non-permissive epithelial cell lines.  This 
increase in the number of cell lines allows identification of genetic differences while also 
ruling out false positives due to chance up- or down-regulation in a given cell line. 
We were able to identify only a small number of cell lines of hematopoietic origin 
as highly non-permissive, but could identify no permissive hematopoietic cells for 
comparison.  Conversely, we were able to identify several permissive adherent, epithelial 
cells lines, but with no non-permissive epithelial cell lines for comparison.   This made 
genetic comparisons difficult in that these permissive epithelial cell lines and non-
permissive hematopoietic cell lines likely differ in expression of hundreds of genes 
related to cell type rather than to Hantavirus permissiveness.  Given these limitations, we 
decided to pursue a different approach using a larger panel of previously characterized 
cell lines.   
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The NCI60 is a panel of cancer cell lines established by the National Cancer 
Institute (NCI) as a standardized means of measuring the efficacy of cancer treatments.  
This panel is comprised of 60 cell lines from 9 different tissue types, including renal, 
lung, and hematopoietic cell lines, among others (Table 3-1).  Several types of cancers 
within each of those tissue types are represented, including squamous carcinomas, 
adenocarcinomas, lymphoblastic leukemia, myelogenous leukemia, etc.  These cell lines 
have been extensively characterized by a number of methods including karyotyping, SNP 
arrays, morphological studies, and mutation analysis, and HLA genotyping (Adams et al., 
2005; Ikediobi et al., 2006; Lorenzi et al., 2009; Roschke et al., 2003).  For our purposes, 
the most useful characterization has been the extensive use of cDNA microarrays to 
analyze gene expression for these cells lines (Liu et al., 2010; Ross et al., 2000; Scherf et 
al., 2000; Shankavaram et al., 2007). 
The NCI60 is most commonly used to compare the effects of small molecules on 
cancer cells.  In a carefully standardized assay, each cell line is treated with a given drug 
and the effect of that drug is determined as measured by growth inhibition (GI50).  The 
GI50 is measured for each cell line, giving a profile of GI50s across all cell lines.  By 
comparing this profile to the profile of other small molecules, the mechanism of action 
and target genes for that drug can often be inferred from similar profiles of previously 
studied drugs (Scherf et al., 2000; Shoemaker, 2006). 
A similar approach has been used to study virus entry.  Rather than identifying 
cell lines as permissive or non-permissive, the NCI60 panel can be used to obtain a 
profile of infection levels for a given virus across cell lines.  Rather than a binary 
measure of permissive and non-permissive, there is a range of highly permissive to non-  
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Table 3-1:  NCI-60 Cell Lines. 
Tissue Cell Line Histology Seeding Density (cells/mL) 
Colon 
COLO 205 Adenocarcinoma   
HCC-2998 Carcinoma   
HCT-116 Carcinoma 2.0E+05 
HCT-15 Adenocarcinoma 2.0E+05 
HT29 Adenocarcinoma, GR III 3.0E+05 
KM12 Adenocarcinoma   
SW-620 Adenocarcinoma   
CNS 
SF-268 Anaplastic Astrocytoma   
SF-295 Glioblastoma-Multiforme 1.0E+05 
SF-539     
SNB-19 Glioblastoma (same as U251) 1.0E+05 
SNB-75 Glioblastoma 5.0E+04 
U251 Glioblastoma   
Hematopoetic 
CCRF-CEM Acute Lymphoblastic Leukemia 5.0E+05 
HL-60(TB) Promyelocytic Leukemia 5.0E+05 
K-562 Chronic Myelogenous Leukemia  5.0E+05 
MOLT-4 Acute Lymphoblastic Leukemia 5.0E+05 
RPMI-8226 Myeloma 5.0E+05 
SR Large Cell, Immunoblastic 5.0E+05 
Mammary 
MCF7 Adenocarcinoma 3.0E+05 
BT-549 Papillary Infiltrating Ductal Carcinoma   
HS 578T Carcinosarcoma 5.0E+05 
MDA-MB-231 Adenocarcinoma   
MDA-MB-468 Adenocarcinoma   
T-47D Infiltrating Ductal Carcinoma 5.0E+05 
Melanoma 
LOX IMVI Malignant Amelanotic Melanoma 5.0E+05 
M14     
MALME-3M Malignant Melanoma 5.0E+05 
MDA-MB-435 Adenocarcinoma 5.0E+05 
SK-MEL-2 Malignant Melanoma   
SK-MEL-28 Malignant Melanoma   
SK-MEL-5 Malignant Melanoma   
UACC-257     
UACC-62     
Ovarian 
IGROV1 Cystoadenocarcinoma 1.6E+05 
NCI/ADR-RES Adenocarcinoma   
OVCAR-3 Adenocarcinoma 5.0E+05 
OVCAR-4     
OVCAR-5 Adenocarcinoma 5.0E+05 
OVCAR-8 Adenocarcinoma   
SK-OV-3     
Prostate DU-145 Carcinoma 1.6E+05 
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PC-3 Adenocarcinoma 5.0E+05 
Pulmonary 
A549 Adenocarcinoma   
EKVX Adenocarcinoma 2.0E+05 
HOP-62 Adenocarcinoma   
HOP-92 Large Cell, Undifferentiated 1.0E+05 
NCI-H226 Squamous 5.0E+05 
NCI-H23 Adenocarcinoma   
NCI-H322M Small Cell Bronchioalveolar  5.0E+05 
NCI-H460 Large Cell Carcinoma 1.0E+05 
NCI-H522 Adenocarcinoma   
Renal 
786-O Adenocarcinoma   
A498 Adenocarcinoma 2.5E+05 
ACHN Renal Cell Carcinoma 5.0E+05 
CAKI-1 Clear Cell 2.0E+05 
RXF 393 Poorly Differentiated Hypernephroma   
SN12C Carcinoma   
TK-10 Spindle Cell Carcinoma 1.6E+05 
UO-31 Carcinoma   
 
Cell lines in gray were not included in our analysis.  Cell lines were chosen to include a 
broad range of tissue types and histological classifications.  Seeding density was 
determined for each cell line to give ~80% confluence at the time of infection. 
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permissive, with differing levels of permissiveness in between.  This pattern of infection 
across cell lines can be compared to the expression pattern across the same cell lines for 
any given gene.  A gene with an expression profile that correlates with the infection 
profile could, in theory, encode a protein important for virus infection. 
This technique, specifically using the NCI60 to identify host-virus interactions, 
has been used previously to identify EGFR as a receptor for Adeno-Associated Virus-6 
(AAV-6), PDGFR as a receptor for AAV-5, and TIM-1 as a receptor for Ebola Virus (Di 
Pasquale et al., 2003; Kondratowicz et al., 2011; Weller et al., 2010).  The study 
identifying TIM-1 as an Ebola Virus receptor was of particular interest.  That study 
employed an Ebola-VSV pseudotype system nearly identical to our Hantavirus-VSV 
pseudotype system, giving us confidence that this technique could be utilized with 
success.  Given the results of these previous publications, we attempted a similar study. 
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Results 
We selected 32 cell lines from the NCI-60, including 2 cell lines from each of 9 
different tissue types.  We took care to select different cancer types within each tissue 
category, for example, ductal carcinoma and adenocarcinoma from the mammary tissue 
type.  Because the only non-permissive cell lines previously identified were 
hematopoietic cell lines, we were particularly interested in identifying hematopoietic cell 
lines that were permissive to infection.  Hematopoietic cell lines are thus overrepresented 
in our samples.  This created a diverse cell panel from within the NCI-60.  As a control, 
we included VERO E6 cells in all experiments to ensure consistent infection results 
between replicates and to provide a comparison point for infection (Table 3-1) 
All cells lines were cultured in RPMI, 10% FBS, 1% Pen Strep and maintained at 
37°C, 5% CO2.   For infections, cells were plated in a 12-well format and incubated 
overnight.  Cells were plated such that they would reach ~80% confluence at the time of 
infection (Table 1).  Cell lines were infected with a panel of VSV∆G*RFP pseudotypes – 
ANDV, HTNV, PUUV, SNV, and VSV-G.  Each virus pseudotype stock was titered on 
Vero E6 cells to give infection values within the linear range of our FACS-based assay.  
For adherent cells, 300µL of virus was added to cells and incubated for 1hr.  For 
suspension cells, cells were pelleted, resuspended in 300µL of virus, and incubated for 
1hr.  After 1hr, 900µL of media was added to each well.  At 24 hours post-infection, cells 
were trypsinized (only for adherent cells) and collected.  Infection was measured as 
percent RFP-positive cells by flow cytometry.  At least 3 biological replicates were 
performed for each virus. 
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Infection levels across cell lines showed a wide range.  In general, infection levels 
for all viruses ranged from background (approximately 0.05% cells infected) to ~50% 
infected cells – an approximate 3-log range.  With ANDV, for example, 8/32 cell lines 
showed <1% infection, 17/32 showed 1-20% infection, and 7/32 showed >20% infection 
(Figure 3-1).  Results were similar for other Hantavirus pseudotypes.  VSV, though 
titered for similar infection levels in Vero E6 cells, tended to have lower infection levels 
in the other cell lines tested with 13/32 cell lines having <1% infection, 18/32 having 1-
20% infection, and only 1/32 having >20% infection (Figure 3-1).  Although these lower 
infection levels were somewhat surprising, these values were within the linear range of 
the assay, as was the case for all viruses tested.  As expected, low Hantavirus infection in 
many cell lines was similarly decreased for VSV infection, indicating an effect on 
replication of the VSV∆G*RFP core.  However, this was not the case for all cell lines.  
For example, comparing ANDV to VSV, 7/32 cell lines showed >5-fold differences in 
infection with 3/32 having >10-fold differences.  Overall, these data indicate a wide, 
dynamic range of infection with many differences directly attributable to Hantavirus 
glycoprotein-mediated entry. 
The NCI has a publicly available web-based tool known as the COMPARE 
algorithm for correlation analysis of the NCI60.  For our studies, however, correlation 
analysis of gene expression and infection was performed by the University of 
Pennsylvania Microarray Core using the publicly available cDNA microarray data from 
the NCI (http://discover.nci.nih.gov/cellminer/loadDownload.do). We performed a 
correlation regression analysis in which percent infection was compared to microarray 
RMA data as gene expression values.  We performed this analysis on 3 separate NCI  
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Figure 3-1: Infection of NCI60 cell lines with ANDV- and VSV-VSV∆G*RFP.  Cells were infected with ANDV- or VSV-
VSV∆G*RFP pseudotypes and infection was measured as % RFP-positive by flow cytometry 24 hours post-infection (mean ± SEM, n 
≥ 3).  Infection values varied over a >2-log range across cell lines tested.  The different infection profiles for ANDV and VSV likely 
reflect differences in glycoprotein-mediated entry for each cell line.
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cDNA microarray data sets – Agilent mRNA, Affy HuEx 1.0, and Affy HG Hu133 Plus 
2.0 (Liu et al., 2010; Reinhold et al., 2010).  These platforms differ in their probes and 
genes present for detection.  The correlation analyses are also likely to differ depending 
on differences in measurements of gene expression among data sets.  As a result, analysis 
of 3 different platforms would result in 3 lists of “hits” with varying degrees of overlap 
between platforms.  We identified hits using two criteria: (1) a cutoff of correlation 
coefficients with a corrected p-value < 0.01 and (2) genes that were identified on at least 
2 of 3 platforms.  A p < 0.01 corresponded to a correlation coefficient of at least 0.4 - 0.5, 
depending on the platform analyzed. 
We performed this analysis for each virus pseudotype resulting in lists of genes 
for ANDV, HTNV, PUUV, SNV, and VSV.  Because these experiments employed 
VSV∆G pseudotype constructs, genes correlated with VSV-G-VSV∆G infection were 
considered background - likely correlated with VSV replication rather than glycoprotein-
dependent entry or due to artifacts of the data analysis itself.  These background genes 
were removed from the gene lists that correlated with Hantavirus infection.  Further 
analysis focused specifically on identifying genes for ANDV entry. 
For ANDV-VSV∆G, these analyses identified 51 (Agilent), 197 (HuEx), and 446 
(Hu133) genes with p < 0.01 on individual microarrays.  These genes overlapped to a 
degree such that 553 unique genes were identified in total.  Of those, only 90 genes were 
identified on at least 2 of 3 microarrays, thereby meeting our criteria for hit inclusion. 
Only 16 of those 90 genes were identified on 3 of 3 microarrays (Table 3-2).
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Table 3-2:  Genes correlated with ANDV-VSV∆G infection.   
 
Gene Information U133 Agilent HuEx 
Gene 
Symbol 
EntrezGene 
ID Gene Name p-value CC p-value CC p-value CC 
SLC38A3 10991 Solute carrier family 38, member 3 1.622E-06 0.6012 9.904E-03 0.4726 2.519E-07 0.6352 
GPM6A 2823 Glycoprotein M6A 7.214E-06 0.5665 1.404E-03 0.5383 4.191E-07 0.6253 
IGSF3 3321 Immunoglobulin superfamily, member 3 5.106E-05 0.5203 3.355E-03 0.5097 1.887E-06 0.6049 
GRIK4 2900 Glutamate receptor, ionotropic, kainate 4 4.438E-03 0.4117 6.923E-03 0.4861 9.086E-05 0.5401 
KREMEN1 83999 Kringle containing transmembrane protein 1 3.441E-03 0.4199 8.394E-04 0.5539 9.086E-05 0.5381 
SEPT4 5414 Septin 4 1.036E-04 0.5064 6.592E-04 0.5631 1.488E-04 0.5258 
ENPP6 133121 
Ectonucleotide 
pyrophosphatase/phosphodiester
ase 6 
2.395E-05 0.5352 8.394E-04 0.5546 3.027E-04 0.5119 
GFAP 2670 Glial fibrillary acidic protein 1.201E-04 0.5032 3.045E-03 0.5139 3.755E-04 0.5052 
PHLDB1 23187 Pleckstrin homology-like domain, family B, member 1 2.323E-05 0.5368 5.119E-03 0.4960 1.269E-03 0.4698 
SSX2IP 117178 Synovial sarcoma, X breakpoint 2 interacting protein 9.450E-03 0.3872 3.768E-03 0.5070 1.520E-03 0.4650 
GMPR 2766 Guanosine monophosphate reductase 5.572E-04 0.4671 1.719E-03 0.5285 1.701E-03 0.4612 
FABP7 2173 Fatty acid binding protein 7, brain 3.650E-06 0.5779 1.746E-03 0.5275 1.883E-03 0.4582 
TNIK 23043 TRAF2 and NCK interacting kinase 1.673E-04 0.4968 1.191E-03 0.5447 2.146E-03 0.4532 
SLC6A8 6535 
Solute carrier family 6 
(neurotransmitter transporter, 
creatine), member 8 
2.485E-05 0.5335 1.367E-03 0.5396 2.390E-03 0.4496 
PLEKHB1 58473 
Pleckstrin homology domain 
containing, family B (evectins) 
member 1 
2.807E-04 0.4847 9.607E-03 0.4735 6.662E-03 0.4169 
PPP1R14
C 81706 
Protein phosphatase 1, 
regulatory (inhibitor) subunit 14C 1.712E-04 0.4963 7.654E-03 0.4824 8.231E-03 0.4085 
HECTD2 143279 HECT domain containing 2 4.207E-03 0.4137 6.158E-04 0.5706     
CITED1 4435 Cbp/p300-interacting transactivator, with Glu/Asp-rich 7.733E-04 0.4592 1.651E-03 0.5298     
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carboxy-terminal domain, 1 
PLEKHH2 130271 
Pleckstrin homology domain 
containing, family H (with MyTH4 
domain) member 2 
2.906E-03 0.4249 3.045E-03 0.5137     
CX3CL1 6376 Chemokine (C-X3-C motif) ligand 1 3.887E-04 0.4757 3.045E-03 0.5134     
SLC27A6 28965 Solute carrier family 27 (fatty acid transporter), member 6 1.812E-05 0.5434 5.126E-03 0.4956     
LANCL3 347404 LanC lantibiotic synthetase component C-like 3 (bacterial) 1.972E-03 0.4358 6.277E-03 0.4897     
PLEKHA4 57664 
Pleckstrin homology domain 
containing, family A 
(phosphoinositide binding 
specific) member 4 
1.916E-03 0.4364 7.462E-03 0.4835     
LRP2BP 55805 LRP2 binding protein 3.740E-04 0.4768 7.462E-03 0.4833     
SORBS1 10580 Sorbin and SH3 domain containing 1 7.818E-03 0.3940 7.826E-03 0.4817     
RUNX2 860 Runt-related transcription factor 2 1.783E-04 0.4951 8.713E-03 0.4772     
ABCB9 23457 ATP-binding cassette, sub-family B (MDR/TAP), member 9 2.226E-04 0.4902 9.607E-03 0.4735     
KIAA1161 57462 KIAA1161 4.217E-06 0.5747     3.755E-04 0.5058 
TULP4 56995 Tubby like protein 4 1.190E-05 0.5536     4.027E-03 0.4334 
GPR137B 7107 G protein-coupled receptor 137B 1.520E-05 0.5473     5.946E-04 0.4930 
PIPOX 51268 Pipecolic acid oxidase 2.399E-05 0.5344     1.149E-03 0.4724 
TRIM2 23321 Tripartite motif-containing 2 3.599E-05 0.5273     6.039E-04 0.4896 
USP46 64854 Ubiquitin specific peptidase 46 1.010E-04 0.5071     8.541E-03 0.4065 
CHST1 8534 Carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 1.589E-04 0.4981     6.039E-04 0.4903 
AMPD1 270 Adenosine monophosphate deaminase 1 (isoform M) 1.643E-04 0.4973     3.809E-04 0.5025 
CXXC5 51523 CXXC finger 5 2.793E-04 0.4849     1.458E-03 0.4666 
CLCN3 1182 Chloride channel 3 2.904E-04 0.4837     1.701E-03 0.4614 
EPHB3 2049 EPH receptor B3 3.382E-04 0.4796     3.027E-04 0.5114 
IQCG 84223 IQ motif containing G 3.690E-04 0.4775     8.078E-03 0.4094 
CNR1 1268 Cannabinoid receptor 1 (brain) 3.690E-04 0.4774     1.149E-03 0.4743 
VSNL1 7447 Visinin-like 1 4.564E-04 0.4720     1.972E-03 0.4568 
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MAP6D1 79929 MAP6 domain containing 1 5.191E-04 0.4692     2.218E-03 0.4521 
TSPAN9 10867 Tetraspanin 9 6.385E-04 0.4637     8.203E-03 0.4088 
SPECC1 92521 
Sperm antigen with calponin 
homology and coiled-coil 
domains 1 
6.720E-04 0.4624     6.039E-04 0.4901 
CAPS 828 Calcyphosine 7.888E-04 0.4587     1.604E-04 0.5238 
AIF1L 83543 allograft inflammatory factor 1-like 8.216E-04 0.4576     4.299E-03 0.4308 
HTR7 3363 
5-hydroxytryptamine (serotonin) 
receptor 7 (adenylate cyclase-
coupled) 
8.621E-04 0.4566     4.729E-03 0.4271 
GPM6B 2824 Glycoprotein M6B 1.079E-03 0.4512     4.955E-03 0.4259 
FAM102A 399665 Family with sequence similarity 102, member A 1.156E-03 0.4495     2.883E-03 0.4438 
CLTC 1213 Clathrin, heavy chain (Hc) 1.229E-03 0.4479     6.039E-04 0.4904 
SCUBE2 57758 Signal peptide, CUB domain, EGF-like 2 1.619E-03 0.4408     5.305E-03 0.4239 
WDR45L 56270 WDR45-like 1.623E-03 0.4407     8.231E-03 0.4085 
TAB2 23118 TGF-Beta Activated Kinase 1/MAP3K7 Binding Protein 2 2.009E-03 0.4352     6.761E-05 0.5478 
NID1 4811 Nidogen 1 2.029E-03 0.4348     8.553E-03 0.4064 
SYTL5 94122 Synaptotagmin-like 5 2.115E-03 0.4338     1.466E-04 0.5270 
PI15 51050 Peptidase inhibitor 15 2.275E-03 0.4318     1.149E-03 0.4731 
CDK2AP1 8099 CDK2-associated protein 1 2.422E-03 0.4302     7.894E-03 0.4101 
GPR56 9289 G protein-coupled receptor 56 2.490E-03 0.4296     7.712E-03 0.4109 
PFKFB4 5210 
6-phosphofructo-2-
kinase/fructose-2,6-
biphosphatase 4 
2.647E-03 0.4278     1.432E-03 0.4673 
TFAP2C 7022 
Transcription factor AP-2 gamma 
(activating enhancer binding 
protein 2 gamma) 
2.713E-03 0.4270     8.871E-03 0.4049 
OSBPL10 114884 Oxysterol binding protein-like 10 2.739E-03 0.4266     7.141E-03 0.4138 
C6orf168 84553 Chromosome 6 open reading frame 168 2.749E-03 0.4265     1.466E-04 0.5269 
DNAJC22 79962 DnaJ (Hsp40) homolog, subfamily C, member 22 2.779E-03 0.4262     1.863E-03 0.4589 
MFAP3L 9848 Microfibrillar-associated protein 3-like 2.848E-03 0.4255     8.454E-03 0.4070 
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KLHL2 11275 Kelch-like 2, Mayven (Drosophila) 3.090E-03 0.4230     8.932E-03 0.4043 
PTGFRN 5738 Prostaglandin F2 receptor negative regulator 3.119E-03 0.4227     2.084E-03 0.4555 
C4orf19 55286 Chromosome 4 open reading frame 19 3.345E-03 0.4208     4.066E-03 0.4328 
USO1 8615 USO1 homolog, vesicle docking protein (yeast) 3.938E-03 0.4155     6.485E-04 0.4879 
AUTS2 26053 Autism susceptibility candidate 2 3.973E-03 0.4153     3.809E-04 0.5042 
ZNF621 285268 Zinc finger protein 621 4.031E-03 0.4148     3.961E-04 0.5009 
CTDSPL 10217 
CTD (carboxy-terminal domain, 
RNA polymerase II, polypeptide 
A) small phosphatase-like 
4.246E-03 0.4132     8.345E-03 0.4081 
WDR31 114987 WD repeat domain 31 4.587E-03 0.4108     1.149E-03 0.4737 
DDR1 780 Discoidin domain receptor family, member 1 4.626E-03 0.4105     1.193E-03 0.4713 
ST6GALN
AC2 10610 
ST6 (alpha-N-acetyl-neuraminyl-
2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-
sialyltransferase 2 
5.762E-03 0.4041     6.107E-03 0.4198 
PECR 55825 Peroxisomal trans-2-enoyl-CoA reductase 5.767E-03 0.4040     2.451E-03 0.4487 
CUEDC1 404093 CUE domain containing 1 5.801E-03 0.4036     9.086E-05 0.5384 
C1orf88 128344 Chromosome 1 open reading frame 88 6.686E-03 0.3992     5.864E-03 0.4210 
DAG1 1605 Dystroglycan 1 (dystrophin-associated glycoprotein 1) 6.871E-03 0.3983     3.598E-03 0.4379 
LZTS2 84445 Leucine zipper, putative tumor suppressor 2 7.074E-03 0.3972     7.714E-03 0.4108 
FBXO32 114907 F-box protein 32 8.033E-03 0.3929     3.776E-03 0.4359 
SOX13 9580 SRY (sex determining region Y)-box 13 8.039E-03 0.3928     8.541E-03 0.4066 
FEZ1 9638 Fasciculation and elongation protein zeta 1 (zygin I) 8.539E-03 0.3906     3.514E-03 0.4387 
RUFY3 22902 RUN and FYVE domain containing 3 9.456E-03 0.3871     3.783E-03 0.4357 
FUNDC1 139341 FUN14 domain containing 1 9.986E-03 0.3854     3.252E-03 0.4410 
TMEM99 147184 Transmembrane protein 99     8.007E-03 0.4803 1.149E-03 0.4723 
KIF13B 23303 Kinesin family member 13B     5.094E-03 0.4972 1.883E-03 0.4582 
ARHGAP1 93663 Rho GTPase activating protein     1.191E-03 0.5453 2.146E-03 0.4539 
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ANDV-VSV∆G infection was analyzed for correlation with gene expression on three different cDNA microarray analyses of the 
NCI60 (U133, Agilent, HuEx).  A correlation coefficient (CC) was determined for each gene.  120 genes were correlated with ANDV-
VSV∆G infection based on a CC with a p-value cutoff of p < 0.01 identified on at least 2 of 3 microarrays.  Of these, 16 genes were 
identified on 3 of 3 microarrays, listed at the top of the table.  20 genes that also correlated with VSV-VSV∆G pseudotype infection 
are also listed and highlighted in gray.  These were removed from further consideration leaving a list of 70 candidate host factors for 
further analysis
8 18 
ACOX1 51 Acyl-Coenzyme A oxidase 1, palmitoyl     4.869E-03 0.4993 2.146E-03 0.4533 
ARFIP1 27236 ADP-ribosylation factor interacting protein 1 (arfaptin 1)     8.996E-03 0.4757 3.514E-03 0.4387 
HDAC5 10014 Histone deacetylase 5     6.158E-04 0.5716 4.237E-03 0.4316 
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The same analysis with VSV-G-VSV∆G identified 117 (Agilent), 205 (HuEx), and 315 
(Hu133) for a total of 439 unique genes.  Of those, 120 genes were identified on at least 2 
of 3 platforms, with 38 of those being identified on 3 of 3 platforms.  When comparing 
the 90 genes associated with ANDV-VSV∆G and the 120 genes associated with VSV-
VSV∆G, 20 genes identified were common to both leaving 70 genes unique to ANDV-
glycoprotein-dependent entry (Table 3-2). 
We further analyzed this list of genes for enrichment of gene ontology categories, 
protein-protein interactions, and cellular localization to identify pathways and/or gene 
families utilized by these viruses.  We used the publicly available DAVID web-based 
program for this analysis (Huang, Sherman, & Lempicki, 2009a, 2009b).  Based on these 
analyses we were unable to identify specific pathways or gene sets enriched in our 
ANDV-associated genes. 
We hypothesized that any gene playing a role in virus entry, as a receptor or 
attachment factor, would likely be a cell surface transmembrane protein or membrane-
associated protein.  Based on DAVID analysis for cellular localization, literature searches 
for protein function, and amino acid sequence analysis for transmembrane domains, we 
identified 31 of 70 genes in our list that were transmembrane or membrane-associated 
proteins (Table 3-3).  We considered these 31 genes as higher priority hits. 
We initially set out to individually test genes from our transmembrane protein list 
that seemed likely to have an effect on entry based on protein type and tissue localization.  
Based on the previously described criteria, we identified the transmembrane protein 
IGSF3 (Immunoglobulin Super Family 3) as the highest priority hit. This protein had 
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Table 3-3:  Prioritized list of candidate host entry factors for ANDV infection.   
 
Gene Information Priority Criteria p-value 
Gene Symbol Gene Name Localization 
Tested in 
siRNA 
screen 
SNV 
overlap U133 Agilent HuEx 
IGSF3 Immunoglobulin superfamily, member 3 membrane no yes 5.106E-05 3.355E-03 1.887E-06 
KIAA1161 KIAA1161 membrane no yes 4.217E-06   3.755E-04 
USO1 USO1 homolog, vesicle docking protein (yeast) membrane no yes 3.938E-03   6.485E-04 
DNAJC22 DnaJ (Hsp40) homolog, subfamily C, member 22 membrane no yes 2.779E-03   1.863E-03 
SSX2IP Synovial sarcoma, X breakpoint 2 interacting protein membrane no no 9.450E-03 3.768E-03 1.520E-03 
PLEKHB1 
Pleckstrin homology domain 
containing, family B (evectins) 
member 1 
membrane no no 2.807E-04 9.607E-03 6.662E-03 
PLEKHH2 
Pleckstrin homology domain 
containing, family H (with MyTH4 
domain) member 2 
membrane no no 2.906E-03 3.045E-03   
CX3CL1 Chemokine (C-X3-C motif) ligand 1 membrane no no 3.887E-04 3.045E-03   
SORBS1 Sorbin and SH3 domain containing 1 membrane no no 7.818E-03 7.826E-03   
TSPAN9 Tetraspanin 9 membrane no no 6.385E-04   8.203E-03 
C6orf168 Chromosome 6 open reading frame 168 membrane no no 2.749E-03   1.466E-04 
PTGFRN Prostaglandin F2 receptor negative regulator membrane no no 3.119E-03   2.084E-03 
TMEM99 Transmembrane protein 99 membrane no no   8.007E-03 1.149E-03 
ARFIP1 ADP-ribosylation factor interacting protein 1 (arfaptin 1) membrane no no   8.996E-03 3.514E-03 
GPR137B G protein-coupled receptor 137B membrane yes no 1.520E-05   5.946E-04 
MFAP3L Microfibrillar-associated protein 3-like membrane yes no 2.848E-03   8.454E-03 
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ST6GALNAC2 
ST6 (alpha-N-acetyl-neuraminyl-
2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-
sialyltransferase 2 
membrane yes no 5.762E-03   6.107E-03 
KREMEN1 Kringle containing transmembrane protein 1 Membrane yes no 3.441E-03 8.394E-04 9.086E-05 
SLC6A8 
Solute carrier family 6 
(neurotransmitter transporter, 
creatine), member 8 
Membrane yes no 2.485E-05 1.367E-03 2.390E-03 
ABCB9 ATP-binding cassette, sub-family B (MDR/TAP), member 9 Membrane yes no 2.226E-04 9.607E-03   
CLCN3 Chloride channel 3 membrane yes no 2.904E-04   1.701E-03 
CLTC Clathrin, heavy chain (Hc) membrane yes no 1.229E-03   6.039E-04 
GPR56 G protein-coupled receptor 56 membrane yes no 2.490E-03   7.712E-03 
DDR1 Discoidin domain receptor family, member 1 membrane yes no 4.626E-03   1.193E-03 
DAG1 Dystroglycan 1 (dystrophin-associated glycoprotein 1) membrane yes no 6.871E-03   3.598E-03 
GRIK4 Glutamate receptor, ionotropic, kainate 4 membrane yes yes 4.438E-03 6.923E-03 9.086E-05 
SLC27A6 Solute carrier family 27 (fatty acid transporter), member 6 membrane yes yes 1.812E-05 5.126E-03   
CHST1 Carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 membrane yes yes 1.589E-04   6.039E-04 
EPHB3 EPH receptor B3 membrane yes yes 3.382E-04   3.027E-04 
HTR7 
5-hydroxytryptamine (serotonin) 
receptor 7 (adenylate cyclase-
coupled) 
membrane yes yes 8.621E-04   4.729E-03 
ACOX1 Acyl-Coenzyme A oxidase 1, palmitoyl membrane yes yes   4.869E-03 2.146E-03 
PHLDB1 Pleckstrin homology-like domain, family B, member 1 
non-
membrane no no 2.323E-05 5.119E-03 1.269E-03 
PLEKHA4 
Pleckstrin homology domain 
containing, family A 
(phosphoinositide binding 
specific) member 4 
non-
membrane no no 1.916E-03 7.462E-03   
TULP4 Tubby like protein 4 non-
membrane no no 1.190E-05   4.027E-03 
CXXC5 CXXC finger 5 non-
membrane no no 2.793E-04   1.458E-03 
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FAM102A Family with sequence similarity 102, member A 
non-
membrane no no 1.156E-03   2.883E-03 
C4orf19 Chromosome 4 open reading frame 19 
non-
membrane no no 3.345E-03   4.066E-03 
AUTS2 Autism susceptibility candidate 2 non-
membrane no no 3.973E-03   3.809E-04 
LZTS2 Leucine zipper, putative tumor suppressor 2 
non-
membrane no no 7.074E-03   7.714E-03 
FBXO32 F-box protein 32 non-
membrane no no 8.033E-03   3.776E-03 
SEPT4 Septin 4 non-
membrane yes no 1.036E-04 6.592E-04 1.488E-04 
GMPR Guanosine monophosphate reductase 
non-
membrane yes no 5.572E-04 1.719E-03 1.701E-03 
TNIK TRAF2 and NCK interacting kinase 
non-
membrane yes no 1.673E-04 1.191E-03 2.146E-03 
CITED1 
Cbp/p300-interacting 
transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 1 
non-
membrane yes no 7.733E-04 1.651E-03   
USP46 Ubiquitin specific peptidase 46 non-
membrane yes no 1.010E-04   8.541E-03 
SCUBE2 Signal peptide, CUB domain, EGF-like 2 
non-
membrane yes no 1.619E-03   5.305E-03 
NID1 Nidogen 1 non-
membrane yes no 2.029E-03   8.553E-03 
CDK2AP1 CDK2-associated protein 1 non-
membrane yes no 2.422E-03   7.894E-03 
PFKFB4 
6-phosphofructo-2-
kinase/fructose-2,6-
biphosphatase 4 
non-
membrane yes no 2.647E-03   1.432E-03 
OSBPL10 Oxysterol binding protein-like 10 non-
membrane yes no 2.739E-03   7.141E-03 
ZNF621 Zinc finger protein 621 non-
membrane yes no 4.031E-03   3.961E-04 
CTDSPL 
CTD (carboxy-terminal domain, 
RNA polymerase II, polypeptide 
A) small phosphatase-like 
non-
membrane yes no 4.246E-03   8.345E-03 
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WDR31 WD repeat domain 31 non-
membrane yes no 4.587E-03   1.149E-03 
PECR Peroxisomal trans-2-enoyl-CoA reductase 
non-
membrane yes no 5.767E-03   2.451E-03 
SOX13 SRY (sex determining region Y)-box 13 
non-
membrane yes no 8.039E-03   8.541E-03 
KIF13B Kinesin family member 13B non-
membrane yes no   5.094E-03 1.883E-03 
LRP2BP LRP2 binding protein non-
membrane no yes 3.740E-04 7.462E-03   
MAP6D1 MAP6 domain containing 1 non-
membrane no yes 5.191E-04   2.218E-03 
SPECC1 
Sperm antigen with calponin 
homology and coiled-coil domains 
1 
non-
membrane no yes 6.720E-04   6.039E-04 
WDR45L WDR45-like non-
membrane no yes 1.623E-03   8.231E-03 
CUEDC1 CUE domain containing 1 non-
membrane no yes 5.801E-03   9.086E-05 
C1orf88 Chromosome 1 open reading frame 88 
non-
membrane no yes 6.686E-03   5.864E-03 
FEZ1 Fasciculation and elongation protein zeta 1 (zygin I) 
non-
membrane no yes 8.539E-03   3.514E-03 
FUNDC1 FUN14 domain containing 1 non-
membrane no yes 9.986E-03   3.252E-03 
ARHGAP18 Rho GTPase activating protein 18 non-
membrane no yes   1.191E-03 2.146E-03 
TRIM2 Tripartite motif-containing 2 non-
membrane yes yes 3.599E-05   6.039E-04 
SYTL5 Synaptotagmin-like 5 non-
membrane yes yes 2.115E-03   1.466E-04 
TFAP2C 
Transcription factor AP-2 gamma 
(activating enhancer binding 
protein 2 gamma) 
non-
membrane yes yes 2.713E-03   8.871E-03 
KLHL2 Kelch-like 2, Mayven (Drosophila) non-
membrane yes yes 3.090E-03   8.932E-03 
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HDAC5 Histone deacetylase 5 non-
membrane yes yes   6.158E-04 4.237E-03 
 
Genes were first identified as correlated with ANDV infection.  Genes that were also identified as correlated with VSV infection were 
removed.  Genes were identified as “membrane” or “non-membrane” proteins using gene ontology software and manual curation. 
Genes were also cross-referenced with genes also tested in a siRNA screen for ANDV factors. Membrane proteins that were not tested 
in the siRNA screen were given higher priority as potential receptors or entry factors.  Of these 14 genes, 4 genes (yellow) that were 
also correlated with SNV infection were given slightly higher priority, based on the assumption ANDV and SNV use the same entry 
factors based on their high similarity.  The remaining 10 high priority genes not associated with SNV entry are highlighted green.
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been previously identified as highly expressed in epithelial cells of the lung and kidney, 
known sites of Hantavirus replication in vivo.  In addition, IGSF3 was identified as 
correlated with ANDV on 3 of 3 microarrays and had the highest correlation coefficients 
of any gene. 
We used siRNA knockdown of IGSF3 to identify an effect on infection.  We 
tested 293T and A549 cell lines, kidney and lung epithelial cells respectively, for 
knockdown of infection as both these cell lines are highly permissive to ANDV and VSV 
pseudotype infection and are easily transfected.  We transfected 293T cells with 4 unique, 
unpooled siRNAs in a 12-well format at 40nM final siRNA concentration.  We used non-
targeting control siRNA as a negative control and siRNA targeting ATP6V0C, a member 
of the endosomal proton pump required for pH-dependent entry, as a positive control for 
inhibition of infection.  Knockdown was confirmed by western blot for IGSF3 (Figure 3-
2A).  Protein knockdown was most effective for IGSF3 (si-3) and IGSF3 (si-4).  We 
infected cells with ANDV-VSV∆G*RFP and VSV-G-VSV∆G*RFP pseudovirions and 
24hrs post-infection, measured RFP expression by flow cytometry (Figure 3-2B). 
Although there was not complete knockdown for all siRNAs as measured by western 
blot, infection did not correlate at all with any level of knockdown.  Using the same anti-
IGSF3 siRNAs, we also transfected A549 in 96-well plate format.  We infected with 
ANDV-VSV∆G*rLuc and VSV-G-VSV∆G*rLuc (Figure 3-3).  To account for cell 
viability, duplicate wells were plated and cell viability was measured by Cell Titer Glo 
(not shown).  There was no effect of IGSF3 knockdown on infection in A549 cells. 
Results from these experiments indicated no effect on infection by ANDV or VSV 
pseudotypes. 
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Figure 3-2:  Effect of IGSF3 knockdown on ANDV-VSV∆G infection in 293T cells. 
(A) 293T cells were transfected with 4 unique siRNAs targeting IGSF3.  Three days were 
allowed for protein knockdown.  Knockdown efficiency was determined by western blot.  
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(B) Three days post-transfection of siRNA, cells were infected with ANDV- or VSV-
VSV∆G*RFP pseudotypes.  Infection was measured as % RFP-positive cells by flow 
cytometry 24hrs post-infection.  siRNA ATP6V0C was used as a positive control.  Data 
are plotted as percent relative to negative Control.  While infection was inhibited 5-fold 
for the siRNA targeting ATP6V0C, there was no effect of IGSF3 knockdown on ANDV 
or VSV infection.  Although ANDV-VSV∆G infection was inhibited by IGSF3 (si-2), 
infection was also down for VSV-VSV∆G. Further repeats would be required for 
definitive conclusions, but given previous results, we abandoned further analysis of 
IGSF3 knockdown. 
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Figure 3-3:  Effect of IGSF3 knockdown on ANDV-VSV∆G infection in A549 cells.  
A549 cells were transfected with 4 unique siRNAs targeting IGSF3.  Three days were 
allowed for protein knockdown and cells were infected with ANDV- or VSV-
VSV∆G*rLuc pseudotypes.  RLUs were measured 24 hours post-infection.  siRNAs 
targeting rLuc and ATP6V0C were used as positive controls.  RLU values are plotted as 
percent relative to negative Control (mean ± SEM for 3 technical replicates, 1 biological 
replicate).  While infection was inhibited 5-fold for both positive controls, there was no 
effect of IGSF3 knockdown on ANDV or VSV infection. 
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After these results, we set out to test multiple genes at a single time to identify 
which, if any, of these “high priority” membrane genes might actually be important for 
entry.  Previous data from our lab identified CHO cells as a cell line in which our ANDV-
VSV∆G pseudotypes showed relatively low levels of infection compared to Vero cells, 
but in which VSV-G-VSV∆G infection was unaffected leading us to hypothesize a defect 
in entry in these cells.  We attempted to use cDNA rescue in these cells to bypass the 
entry defect. 
We obtained cDNA constructs for 13 of our gene candidates, 5 of which were in 
the pCMV-SPORT6 expression vector and were readily transfectable into mammalian 
cells for cDNA rescue experiments (CHST1, EPHB3, GRIK4, IGSF3, and MFAP3L).  
CX3CL1 and DDR1 were cloned from the pOTB7 cloning vector in the pCMV-SPORT6 
expression vector.  CHO cells were transfected with each construct.  As controls, we 
transfected a GFP-expressing plasmid to confirm transfection and a CD4 expressing 
construct as a negative control for a membrane protein that should have no effect on 
infection.  18 hours post-transfection to allow for gene expression, we infected cells with 
ANDV-VSV∆G*rLuc and VSV-G-VSV∆G*rLuc pseudotypes and measured infection 
24 hours later by renilla luciferase activity.  Compared to CD4 negative control, no gene 
construct had any effect on infection in CHO cells for either virus (Figure 3-4).  It should 
be noted, however, that expression of these genes was not confirmed so we cannot yet 
conclude that these genes play no role in infection.  Further experiments will be required 
to (1) confirm expression of these constructs and (2) create cDNA constructs of the 
remaining genes for rescue experiments. 
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Figure 3-4:  cDNA rescue in CHO cells.  CHO cells were transfected with the 
designated cDNA construct.  18hrs post-transfection, CHO cells were infected with either 
ANDV- or VSV-VSV∆G*rLuc pseudotypes and RLUs were measured 24hrs post-
infection.  Data is plotted as fold infection relative to CD4 which should have no effect 
on ANDV- or VSV-VSV∆G*rLuc infection.  There was no effect on ANDV-VSV∆G 
infection for any cDNA tested. 
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Discussion 
Significant further experiments will be required to completely test the full list of 
candidate genes for relevance to ANDV infection.  The methods we have employed thus 
far are too inefficient and not cost-effective for testing a large gene set.  We are 
attempting to address this in multiple ways. 
First, we have added additional criteria to narrow down the list of candidate 
genes.  ANDV and SNV are closely related Hantavirus strains with very similar 
glycoproteins.  We hypothesize that important entry factors utilized by these 
glycoproteins are common to both viruses.  Using the SNV infection data, we identified 
105 genes correlated with SNV-VSV∆G infection, 52 of which also correlated with 
VSV-VSV∆G, leaving 53 genes specific to the SNV glycoprotein.  Of these 53 SNV 
genes, 24 were also identified as specific for ANDV infection.  10 of these are membrane 
or membrane-associated genes (Table 3-3). 
Additionally, during the analysis and development of the ANDV candidate gene 
list from the NCI60, we completed a siRNA screen of >9,000 genes for effects on 
ANDV-VSV∆G*rLuc (see Chapter 2).  Ideally, there would be some overlap between 
genes identified in the siRNA screen and NCI60 gene list.  Unfortunately, of the genes 
we identified in the siRNA screen as important for ANDV entry, none were also 
identified in the list of ANDV candidate genes from the NCI60.  However, 38 of 70 
ANDV genes identified in our NCI60 analysis were included in the screened siRNA 
library with no effect on infection.  Ruling those genes out and using our previously 
described criteria, we have now identified 14 membrane genes (green and yellow) in the 
NCI60 list that were not previously screened (Table 3-3).  Furthermore, 4 of these genes  
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 (yellow) are also correlated with SNV infection.  Interestingly, IGSF3 remains at the top 
of this list although our follow-up experiments have shown no effect on infection. 
In order fully test these genes, we plan to clone these cDNAs into a pcDNA3.1 
vector containing a Hygromycin selectable marker.  This would allow for selection of 
transfected cells, giving confidence that the gene of interest is likely to be expressed and 
removing the potential complication of decreased infection due to transient transfection.  
Alternatively, we could clone these genes into a vector co-expressing GFP or with a C-
terminal tag (e.g. HA) in order to confirm gene expression.  Using flow cytometry, we 
would be able to identify effects of gene expression on infection in those cells that have 
been transfected compared to those that remain untransfected. 
However, even if the cDNA cloning approach was shown to be functional, 
cloning can be time and labor intensive, particularly with 14 or more genes to potentially 
be tested.  In order to fully test our list of ANDV hits, we are currently exploring higher 
throughput methods.  One potential method might be a targeted siRNA screen using 
validated siRNAs for each of the 32 genes not previously tested in the siRNA screen.  
This could easily be done in a 96-well format using luciferase pseudotypes and the 
protocol previously described for the secondary siRNA screen used to validate ANDV 
hits.  
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Materials and Methods 
Virus Pseudotype Production.  293T/17 cells were maintained in DMEM, 10% 
FBS, 1% PenStrep at 37°C at 5% CO2.  One day prior to transfection, 293T/17 were 
plated for  ~70% confluence.  The following day, cells were transfected with the 
Hantavirus glycoprotein of interest in the pWRG or pCAGGS expression vector (ANDV-
M-pWRG, HTNV-M-pWRG, SNV-M-pCAGGS, PUUV-M-pCAGGS, VSV-G-
pCAGGS) using Lipofectamine 2000 transfection reagent according to the 
manufacturer’s protocol.  18 hours post-transfection, cells were transduced with VSV-G-
VSV∆G*rLuc or VSV-G-VSV∆G *RFP at a MOI of ~2.5 for 1hr at 37°C.  The VSV-G-
VSV∆G*rLuc or *RFP inoculum was removed and replaced with DMEM, 10%FBS, 
1%PenStrep and the cells were incubated until significant CPE was detected, at 
approximately 2 days post-transduction.  Supernatant containing virus was clarified by 
spinning at 1500 rpm for 10min and put through a 0.45µm filter to clear cellular debris.  
Tris/HCl pH8.0 was added for a final concentration of 25mM and virus was aliquoted 
and stored at -80°C.  For VSV∆G*rLuc pseudovirions, virus preps were titered to give 
RLUs within the linear range of the assay. For RFP experiments, virus was titrated on 
Vero E6 cells and infection was measured by flow cytometry to estimate infectious 
units/mL. 
NCI60 Infections.  All NCI60 cell lines were maintained in RPMI, 10% FBS, 1% 
Pen Strep at 37°C, 5% CO2.  Cells were trypsinized and plated in a 12-well format and 1 
day prior to infection.  Cells were plated for ~80% confluence at the time of infection 
(See Table 3-1 for seeding densities).  Cell lines were infected with a panel of hantavirus 
pseudotypes expressing RFP: ANDV-, HTNV,- PUUV-, SNV- , and VSV-G- 
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VSV∆G*RFP .  Virus stocks were titered on Vero E6 cells at ~1x105 Infectious 
Units/mL.  For adherent cell lines, 300µL of virus was added to cells and incubated for 
1hr.  For suspension cells, cells were centrifuged and resuspended in 300µL of virus for 
1hr.  After 1hr, 900µL of media was added to each well and incubated for 24hrs.  At 24 
hrs post infection, cells were trypsinized (adherent cells), collected, and fixed in 1% 
paraformaldehyde in FACS buffer (PBS-/- with 2.5% FBS, 2mM EDTA).  Percent 
infection was measured as % RFP-positive by flow cytometry using a BD LSR II.  3-4 
biological replicates were performed for each virus and cell line. 
NCI60 Correlation Analysis.  Detailed methods used to generate the microarray 
gene expression data for the NCI60 have been previously described ((Liu et al., 2010; 
Reinhold et al., 2010)).  Multiple microarray data sets have been generated, however we 
used the U133, Agilent, and HuEx microarrays analyses as these were the most recent 
and comprehensive.  Data sets can be found the NCI website 
(http://discover.nci.nih.gov/cellminer/loadDownload.do).  Correlation analysis was 
performed by the University of Pennsylvania Microarray Core.  Infection profiles across 
cell lines for each virus was correlated with gene expression RMA values using a 
correlation regression analysis generating a Pearson’s correlation coefficient for each 
gene and a corresponding step-up p-value corrected for multiple comparisons testing.  
Step-up p-value < 0.01 was used as an arbitrary cutoff for significance generally 
corresponding to a correlation coefficient of ~0.4. 
IGSF3 knockdown infections.  Four unique siRNAs targeting IGSF3 were 
obtained from Dharmacon (sequences:  GCGCAUUCUAGGACAUGAA, 
CCUUAAUGUGGACGAAUUU, GGGAAGAUGACUGGCGUUU, 
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CCAUAGACUAAGCGGGUGA).  For VSV∆G*rLuc infections, siRNAs were plated in 
a 96-well format and complexed with 1.25µL of HiPerFect in 25µL OptiMem.  7.5x103 
HEK293T or A549 cells were reverse-transfected onto siRNA complexes in 75µL 
volume giving a 40nM final siRNA concentration.  Cells were incubated for 72hrs to 
allow for knockdown.  Cells were then infected with VSV∆G*rLuc pseudovirions 
pseudotyped with ANDV, SNV, or VSV glycoproteins (MOI~0.1).  24hrs post-infection, 
infected cells were lysed and Renilla luciferase activity was measured using the Renilla 
Luciferase assay system (Promega) on a Luminoskan Ascent Luminometer (Thermo 
Scientific).  For VSV∆G*RFP infections, the same protocol above was used in a 12-well 
format with the above volumes scaled up 10-fold for the same 40nM final siRNA 
concentration.  Cells were fixed in 1% paraformaldehyde in FACS buffer and RFP 
expression was measured by flow cytometry. 
IGSF3 knockdown Western Blot.  293T cells were lysed using 1% Triton-X 100 
lysis buffer (50mM Tris, 150mM NaCl, 5mM EDTA) with protease inhibitors (Roche) 
for 10min at 4°C.  The membrane debris was cleared by high speed microcentrifuge spin 
at 13000rpm for 10min at 4°C and the supernatants were collected.  The lysates were run 
under non-reducing conditions on a SDS-PAGE 4-12% Bis-Tris gel for 1hr at 150V and 
transferred to a polyvinylidene fluoride membrane for 45min at 24V.  Membranes were 
blocked for 1hr in 5% non-fat dry milk in PBS with 0.1% Tween-20.  Membranes were 
then probed with the specified antibody for 1hr at room temperature or overnight at 4°C.  
HRP activity was visualized by ECL (ThermoScientific, SuperSignal West Femto).  Anti-
IGSF3 mouse monoclonal antibody was obtained from R&D systems (clone 503621).  
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Anti-GAPDH mouse monoclonal antibody was obtained from Calbiochem (clone 6C5). 
Anti-mouse HRP-conjugated antibody was obtained from Jackson Lab. 
cDNA rescue in CHO cells.  Indicated cDNA constructs were obtained from 
OpenBiosystems (Gene, Accession Number: IGSF3, BC110651; CHST1, BC028235; 
EPHB3, BC052968; MFAP3L, BC001279; GRIK4, BC150173; CX3CL1, BC016164; 
DDR1, BC008716).  All constructs except CX3CL1 and DDR1 were initially cloned in 
the pCMV-SPORT6 vector.  CX3CL1 and DDR1 were cloned out of the pOTB7 vector 
into the pCMV-SPORT6 vector using the 5’ EcoRI and 3’ XhoI restriction enzyme sites 
of both vectors.  CHO cells were maintained in IMDM, 10% FBS, 1% P/S at 37°C, 5% 
CO2.  CHO cells were plated in a 96-well format at 4x104 cells/well.  Cells were 
transfected with the cDNA construct using Lipofectamine 2000 according the 
manufacturer’s protocol.  Cells were incubated in transfection media with DNA for 6hrs 
after which the media was replaced with 100µL IMDM media.  Cells were then incubated 
for 18hrs to allow for protein expression  and then infected with 25µL of ANDV- or 
VSV-G-VSV∆G*rLuc.  24hrs post-infection, renilla luciferase expression was measured 
as described above.
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CHAPTER 4 
SUMMARY AND FUTURE DIRECTIONS 
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Summary 
Hantaviruses represent a family of emerging human pathogens with no specific 
treatment or currently available vaccine.  Furthermore, the mechanisms by which these 
viruses enter human cells are poorly understood.  We set out to identify and define the 
pathways and host factors used by Hantaviruses for entry.  We attempted to do so using 
two different, but potentially complementary approaches – high-throughput siRNA 
screening and comparative genomics analysis.   
 In Chapter 2, we used an ANDV-VSV pseudotype system to perform a high-
throughput siRNA screen in a human cell line at BSL-2 conditions.  This approach 
identified 9 genes as potentially important for ANDV glycoprotein-mediated entry.  
Among these genes, we identified SREBF2, a transcription factor that plays a key role in 
regulating the cholesterol uptake pathway.  At the same time we identified this gene, 
SREBF2 and the other members of the same pathway (SCAP, S1P, and S2P) were 
independently identified by a separate genetic screen in a human haploid cell line.  
Follow-up experiments using siRNA knockdown, mutant cell lines, and small molecule 
inhibitors demonstrated a clear role for cholesterol in entry of both Hantavirus-VSV 
pseudovirions and live wildtype ANDV.  That these results also extended to live ANDV 
simultaneously provided important validation our Hantavirus-VSV system and its use in 
future endeavors.  Lastly, we were able to determine that cholesterol depletion caused a 
defect in internalization but normal binding of virions leading to a block in entry. 
 In Chapter 3, we utilized the NCI60, a panel of highly characterized cell lines, to 
identify candidate Hantavirus entry factors.  We infected this panel of cell lines with a 
number of Hantavirus-VSV pseudotypes to create an infection profile across cell lines for  
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each virus.  Using publicly available microarray gene expression data for these cell lines 
from the NCI, we were able to correlate infection with individual gene expression for 
several Hantaviruses, focusing mainly on ANDV.  After removing genes likely 
associated with VSV replication, this analysis identified a list of potential host factors 
specific to ANDV-glycoprotein entry.  We began initial follow-up experiments focusing 
only on the 33 membrane or membrane-associated genes correlated with ANDV entry as 
potential receptors.  Thus far, experiments on a small subset of these genes have failed to 
validate them as important host factors.  However, a large number of these genes remain 
untested and future experiments, specifically taking advantage of more high-throughput 
methods, will be required to identify which, if any, of these genes play a role in entry.  
 
Future Directions 
 Cholesterol is a defining component of lipid rafts.  These cholesterol- and 
sphingolipid-rich microdomains of the plasma membrane play a key role in biological 
processes including signaling, uptake, and endocytic trafficking (Brown & London, 1998; 
Simons & Ehehalt, 2002).  A number of proteins are known to localize specifically to 
lipid rafts allowing them to co-localize with binding partners, signal, and traffic 
appropriately.  Cholesterol depletion of the cell membrane disrupts these lipid rafts and 
can inhibit a number of cell functions (Brown & London, 1998).   
While the exact role of cholesterol in ANDV entry is unclear, experiments 
demonstrated that the block to entry in cholesterol-depleted cells is secondary to a defect 
in internalization but not binding of virions.  One explanation for normal binding but 
impaired internalization of virions might be that disruption of lipid rafts inhibits 
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appropriate trafficking of the ANDV receptor(s) or attachment factor(s) on the cell 
surface.  Although binding could still occur with these molecules at the surface, this mis-
localization could prevent signaling required for uptake of the virus.  As an example, 
coxsackievirus binds the lipid raft-associated protein DAF leading to signaling and 
trafficking to its receptor (CAR) for entry (Coyne & Bergelson, 2006; Patel, Coyne, & 
Bergelson, 2009).  Cholesterol depletion inhibits this process. 
Another interesting and relevant example of this hypothesis has also been recently 
identified.  HSV-1 uses nectin-1 as receptor for infection, and its expression in non-
susceptible CHO cells is sufficient to mediate infection.  Interestingly, it has recently 
been shown that expression of β3 integrin in these cells redirects trafficking of nectin-1, 
to lipid rafts and HSV-1 uptake is rendered cholesterol-dependent (Gianni & Campadelli-
Fiume, 2012; Gianni, Gatta, & Campadelli-Fiume, 2010).  This information is 
particularly relevant given that both β3 integrin and DAF have been implicated as 
important for Hantavirus entry  (Gavrilovskaya et. al.,1999; Gavrilovskaya et. al., 1998; 
Krautkrämer & Zeier, 2008; Matthys et. al., 2010).   
It is possible that binding to DAF and/or β3 integrin could traffic Hantavirus 
virions to lipid rafts to facilitate interactions with other proteins to mediate entry.  Based 
on previous studies, β3 integrin likely plays some role in hantavirus entry, at least in 
some cell types; however, data from our lab suggest that the understanding of the 
mechanism for this is incomplete.  In studies of permissive 293T cells and non-
permissive SupT1 cells, β3 integrin did not seem to play any role in Hantavirus entry 
(Higa et. al., 2012).   It is possible that multiple Hantavirus receptors exist and play 
important roles only in specific cell types or cellular contexts, as entry or exit receptors as 
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has been shown for measles virus, for example (Mühlebach et al., 2011; Noyce et al., 
2011).  Further studies will be required to define what role, if any, DAF and β3 integrin 
play in Hantavirus entry and where that fits into the context of cholesterol dependence. 
 Another simple explanation for the defect in entry might be disruption of 
caveolin-mediated endocytosis, which requires intact lipid rafts to function.  MBCD 
inhibits caveolar endocytosis by cholesterol depletion.  This drug had a clear effect on 
hantavirus entry in our studies.  If hantavirus entry were specific to this endocytic 
pathway, cholesterol depletion could inhibit infection.  Thus far, both clathrin-dependent 
and clathrin-independent entry pathways have been implicated for some hantaviruses 
(ANDV and HTNV) in a small number of studies (Jin et al., 2002; Ramanathan & 
Jonsson, 2008).  However, these studies have not been completely definitive given their 
use of nonspecific inhibitors and the lack of repeat experiments in the literature.  Further 
experiments using more specific dominant negatives and siRNAs targeting clathrin, 
caveolin, and their adaptor proteins will be important for determining the exact role of 
this entry pathway. These experiments should be done with several hantavirus 
glycoproteins to determine the specificity to Old World and New World hantaviruses as 
this distinction is also unclear. 
Ideally, the use of these two separate approaches, the NCI60 analysis and the 
siRNA screen, would have identified the same genes or pathways.  This would not only 
validate both approaches, it would also simplify follow-up experiments by immediately 
clarifying high priority targets.  Unfortunately, this did not occur and no genes on the two 
lists of potential host factors were identified as common to both approaches.  
Furthermore, analysis of gene ontology and protein-protein interactions identified no 
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enrichment for a specific pathway, biological process, subcellular localization, or 
network interaction within these gene sets.  However, while these separate approaches 
have not been useful in ruling in hits, there has been use for ruling out hits.  Of the initial 
list of 70 genes identified for ANDV entry by the NCI60 analysis, 38 were tested in the 
siRNA screen and identified as non-hits, leaving the remaining 32 as higher priority 
genes.  This further narrowed down the sublist of 31 membrane candidate genes to just 14 
(Table 3-3). 
 It maybe possible to further utilize these approaches to complement each other in 
another way.  Data from validation of the siRNA screen has identified a clear role for 
cholesterol in entry.  This knowledge maybe useful in further prioritizing the list of genes 
from the NCI60.  Although there may not be significant enrichment for the entire gene 
set, it is possible that a small subset of these genes are known to be lipid raft associated or 
cholesterol-dependent in some way.  The use of gene ontology programs to analyze our 
large NCI60 gene set has been unproductive but necessary given the size of the data set, 
thus far.  We are currently unaware of any searchable database of proteins known to 
localize to lipid rafts, which would allow us to easily analyze the list of NCI60 hits for 
lipid raft dependence.  However, after having now utilized data from the siRNA screen to 
narrow a large list of NCI60 hits to a much smaller gene set, it will be possible to 
manually review each gene within the literature for cholesterol dependence. 
Interestingly, a number of our experiments suggested that the effects of decreased 
cholesterol were slightly greater for the New World Hantaviruses, ANDV and SNV, than 
they were for the Old World Hantaviruses, HTNV and PUUV.  This is not necessarily 
surprising given the close homology of the ANDV and SNV glycoproteins.  This may 
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suggest that there are minor differences between hantaviruses in the entry factors utilized.  
Based on this information and their closely related phylogeny, we felt more confident that 
ANDV and SNV used similar host factors allowing us to focus on genes identified in 
common between those viruses in our analysis. 
 We are not sure which, if any, of the NCI60 genes we identified will actually be 
validated as an ANDV entry factor.  However, we performed the NCI60 analysis for 
multiple hantavirus glycoproteins in addition to ANDV, including HTNV, PUUV, and 
SNV.  If we are able to identify an important gene or pathway among the ANDV 
candidate genes, it would validate this entire approach and the analysis generated for the 
other hantaviruses.  Further studies could then identify important differences and 
similarities among entry mechanisms for different Hantaviruses, for example comparing 
Old and New World Hantaviruses. 
 We identified nine genes of approximately 9,000 potential host factors specific to 
ANDV entry in our siRNA screen.  Of those genes, we chose to focus our efforts 
specifically on SREBF2 because of its coincidental overlap with a Hap1 forward genetic 
screen.   However, the remaining genes have yet to be formally tested thus far.  With such 
a small gene list and given the validation of SREBF2 as an important entry factor, it will 
be important to completely test these genes to determine their roles.  Analysis of this gene 
set using the online DAVID database identified no significant gene ontology, sub-cellular 
localization, or signaling pathway enriched for this gene set.   Furthermore, there was no 
identification of interactions between proteins.  However, searches of the existing 
literature for gene information about these genes yielded some useful information about 
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their roles within the cell, allowing some inference regarding their potential as ANDV 
host factors. 
  ST3GAL2 (ST3 beta-galactoside alpha-2,3-sialyltransferase 2) is a Golgi-
localized type II transmembrane protein that catalyzes the transfer of α-2,3-linked sialic 
acids to carbohydrate-containing substrates such as glycoproteins and glycans (Kono et 
al., 1997).  These sialic acid linkages are known to be important for interactions between 
ligands and receptors, as has been shown with glycoproteins and the brain gangliosides 
GD1a and GT1b which are sialylated by ST3GAL2 (Sturgill et al., 2012).  It has been 
shown that post-translational modifications of proteins such as heparan sulfate on 
glycosaminoglycans can play roles in virus binding and entry (Akhtar & Shukla, 2009; 
Byrnes & Griffin, 1998; Horvath et. al., 2010).  These molecules at the cell surface may 
be important for binding of the virion to the cell.  It is plausible that the proteins ANDV 
utilizes for cellular entry are post-translationally modified by ST3GAL2 and these 
modifications are important for ANDV binding and entry.  Experiments inhibiting the 
activity of ST3GAL2 or enzymatically removing these modifications may be useful in 
defining the role of this gene. 
 Another gene, IQGAP3 (IQ motif containing GTPase activating protein 3) is 
thought to play a role in actin reorganization.   The IQGAP family of proteins (IQGAP1-
3) acts as Cdc42 and Rac1 effector molecules with actin-binding domains.  They act as 
scaffolding proteins involved in cytoskeletal reorganization important for cell migration, 
polarization, and neuronal morphogenesis (White, Brown, & Sacks, 2009).  Of particular 
interest, the related protein IQGAP1 has been shown to play a role in phagocytosis 
(Brandt et. al., 2007).  Furthermore, IQGAP3 is expressed at high levels in the lung, as 
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well as in brain and testis (Wang et al., 2007).  IQGAP3 has not been as extensively 
studied as other IQGAP proteins though it has been shown to directly interact with actin 
(Wang et al., 2007). The role of IQGAP family members in cytoskeletal reorganization 
may imply a role in endocytic events that could make IQGAP3 an interesting host factor 
important for entry of ANDV.   
LGR6 (Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 6) is a 7-
transmembrane GPCR known to localize to the plasma membrane.  LGR6, like other 
members of the LGR family of proteins, potentiates Wnt/B-catenin signaling in response 
to binding of its ligands - a family proteins known as the R-spondins. Studies have shown 
LGR6 can co-localize to intracellular vesicles by either constitutive or induced 
endocytosis from the plasma membrane (Gong et al., 2012).   Furthermore, there is data 
to suggest LGR6 expressed in epithelial stem cells of the lung, at least in mouse models 
(Oeztuerk-Winder et. al., 2012).  The specific role of LGR6 is not fully clear as studies of 
its function are limited, however its localization at the plasma membrane and role as a 
signaling protein endocytosed upon ligand binding makes it plausible to hypothesize a 
role as an attachment factor or receptor that might bind with viral particles to initiate 
entry.   
Study and analysis of the remaining gene hits from the siRNA screen do not seem 
generate any obvious hypotheses about their function related to ANDV entry.  NAP1L4 
(Nucleosome Assembly Protein 1-Like 4) is histone chaperone protein localized to the 
nucleus that has some function in neuronal cell proliferation (Rogner et. al., 2000).  
HSPA2 (Heat Shock 70kD Protein 2) is a heat shock protein involved in the cellular 
stress response. Lastly, CES2 (Carboxylesterase 2), MCAT (malonyl CoA:ACP 
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acyltransferase) and PTGS2 (Prostaglandin H2 Synthase 2 or COX-2) are enzymes with 
activities such as drug metabolism, fatty acid metabolism, or prostaglandin synthesis.  
Further experiments will be required to fully explain the specific roles, if any, that these 
enzymes could play in entry.  It is possible that these genes were identified incidentally 
and are unlikely to be related to ANDV specific entry.  However, given the small number 
of genes validated in the secondary screen specific to ANDV and not VSV, it may be 
worthwhile to further test these genes for their ability to facilitate ANDV entry.  
 One of our goals in this work is to hopefully reveal new aspects of not only 
Hantavirus biology but also cell biology.  The study of viruses has revealed much about 
cell biology in general, beyond just host-virus interactions.  SV40 for example has been 
an important tool in studying caveolar endocytosis (Engel et al., 2011).  The 
identification of a specific host factor for ANDV entry might reveal new information 
about that gene and its role in the cell, for example by demonstrating previously unknown 
protein-protein interactions with other genes.  These interactions might have other 
important cellular functions.  Studies of Hantavirus entry pathways have suggested a 
possible clathrin-independent mechanism of entry for ANDV (Ramanathan & Jonsson, 
2008).  Such a pathway and mechanism of entry could be novel and further delineated by 
the use of ANDV or its glycoproteins.    
 Lastly, we hope that this work may also lead to therapeutic intervention for 
hantavirus infection by providing new druggable targets.  The cholesterol pathways have 
been studied extensively, producing a large number of safe, effective drugs, such as the 
HMG-CoA reductase inhibitors.  Although the general requirement for cholesterol in the 
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cell membrane makes the cholesterol pathways difficult to target, many of these drugs are 
commonly used could potentially lend themselves to therapy.  
Our data thus far using cholesterol-depleting drugs indicate that ANDV entry is 
very sensitive to cholesterol levels in our in vitro assays.  Data from our collaborators 
suggest that defects in entry can be overcome by adding back cholesterol after cholesterol 
depletion in these assays (data not shown).  It is unclear if acute decreases in membrane 
cholesterol will be a feasible approach in in vivo models.  In response to decreased 
cholesterol, SREBF2 upregulates cholesterol synthesis pathway genes, such as HMG-
CoA reductase and also upregulates cholesterol scavenging genes such as LDL-R.  Given 
the likely abundance of cholesterol in the serum of a live animal, it may not be possible to 
deplete membrane cholesterol to the levels required for virus inhibition.  The outcome of 
these studies is difficult to predict, but given the availability and safety of HMG-CoA 
reductase inhibitors and an available Syrian hamster model of ANDV infection, we 
believe such studies would be a reasonable undertaking. 
A different, potentially more feasible, approach might be to use this new 
information about the Hantavirus cholesterol dependence to further our search for 
specific host factor proteins.  If a target is identified, there may already exist a specific 
small molecule capable of inhibiting its interaction with ANDV leading to new therapy. 
 Currently there is no FDA-approved vaccine for the prevention of hantavirus 
infection.  Given the current, low prevalence of Hantavirus infection in this country and 
throughout South America, prophylactic vaccination is unlikely to be a feasible or cost-
effective approach.  Some studies of seroprevalance have indicated that even for high-
risk populations in endemic areas, the rate of exposure and conversion from exposure to 
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clinically relevant infection may be low (Campos et al., 2003; Ferrer et al., 1998; Vitek, 
et. al., 1996).  Based on this, it may be more reasonable to diagnose and treat known 
cases with Hantavirus-specific inhibitors rather than prevention by vaccination.  
Likewise, such inhibitors may be useful as prophylaxis in cases of known exposure to 
Hantavirus, for example, travelers in areas of known outbreaks.  In the specific case of 
ANDV, which is thought to be capable of human-to-human transmission, health care 
workers and close contacts of Hantavirus-infected individuals could also be 
prophylactically treated.   
 Hantaviruses are a family of emerging pathogens. Because there is a low 
prevalence of documented infections each year in this country, there is still a great deal 
unknown about these viruses. We have approached the study of these pathogens with 
multiple, unbiased methods to identify host factors important for virus entry in the hope 
of gaining a more complete understanding of both the virus and host biology as well as 
the interactions between them. Our studies have yielded valuable information thus far 
about the cholesterol-dependence of these viruses. As we learn more about the 
epidemiology, clinical characteristics, and molecular biology of these viruses, we will be 
better able to treat and prevent hantavirus infection. 
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Appendix A:  Genes correlated with VSV-VSV∆G infection.   
 
Gene Information U133 Agilent HuEx 
Gene 
Symbol 
EntrezGene 
ID Gene Name p-value CC p-value CC p-value CC 
SLC38A3 10991 Solute carrier family 38, member 3 9.290E-13 0.7322 4.243E-06 0.6224 9.189E-17 0.7955 
ENPP6 133121 
Ectonucleotide 
pyrophosphatase/phosphodiesterase 
6 
3.004E-12 0.7220 3.083E-08 0.6934 4.981E-14 0.7546 
PIPOX 51268 Pipecolic acid oxidase 3.779E-11 0.6925 2.948E-06 0.6296 7.847E-13 0.7329 
GFAP 2670 Glial fibrillary acidic protein 3.779E-11 0.6917 3.626E-06 0.6259 2.070E-17 0.8052 
GPM6A 2823 Glycoprotein M6A 6.678E-11 0.6861 9.661E-11 0.7491 3.164E-19 0.8279 
IRX1 79192 Iroquois homeobox 1 1.567E-10 0.6785 3.109E-07 0.6618 2.119E-03 0.4462 
CTNND2 1501 
Catenin (cadherin-associated 
protein), delta 2 (neural plakophilin-
related arm-repeat protein) 
2.421E-10 0.6743 2.137E-03 0.4961 3.946E-05 0.5327 
AMPD1 270 Adenosine monophosphate deaminase 1 (isoform M) 3.473E-10 0.6704 2.222E-06 0.6338 1.625E-16 0.7909 
SOX2OT 347689 SOX2 overlapping transcript (non-protein coding) 9.588E-09 0.6358 3.306E-05 0.5894 1.481E-03 0.4545 
TKTL1 8277 Transketolase-like 1 2.181E-07 0.5985 2.391E-03 0.4923 7.406E-05 0.5204 
RPRM 56475 Reprimo, TP53 dependent G2 arrest mediator candidate 1.956E-06 0.5686 4.516E-03 0.4751 1.469E-03 0.4552 
ZNF415 55786 Zinc finger protein 415 2.110E-06 0.5672 4.581E-03 0.4741 8.028E-06 0.5622 
DPYSL5 56896 Dihydropyrimidinase-like 5 1.944E-05 0.5325 2.971E-04 0.5445 7.148E-04 0.4736 
KLHL13 90293 Kelch-like 13 (Drosophila) 2.211E-05 0.5298 5.243E-03 0.4700 3.950E-04 0.4869 
LRP1B 53353 Low density lipoprotein-related protein 1B (deleted in tumors) 3.602E-05 0.5201 1.272E-03 0.5102 1.397E-06 0.5884 
PRSS35 167681 Protease, serine, 35 3.649E-05 0.5196 1.940E-04 0.5549 1.707E-05 0.5480 
CYP2C8 1558 Cytochrome P450, family 2, subfamily C, polypeptide 8 5.236E-05 0.5131 4.840E-03 0.4726 2.587E-03 0.4409 
POU3F2 5454 POU class 3 homeobox 2 1.914E-04 0.4888 3.314E-03 0.4831 2.569E-06 0.5795 
NLGN4X 57502 Neuroligin 4, X-linked 3.495E-04 0.4769 3.230E-03 0.4838 2.524E-04 0.4963 
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SEC22B 9554 SEC22 vesicle trafficking protein homolog B (S. cerevisiae) 4.868E-04 0.4700 1.863E-04 0.5566 5.256E-04 0.4807 
CNR1 1268 Cannabinoid receptor 1 (brain) 7.605E-04 0.4612 1.909E-04 0.5555 8.732E-12 0.7134 
CAPS 828 Calcyphosine 8.294E-04 0.4591 5.526E-04 0.5297 4.354E-06 0.5715 
SPAG17 200162 Sperm associated antigen 17 8.332E-04 0.4589 5.443E-06 0.6182 8.013E-14 0.7504 
PCYT1B 9468 Phosphate cytidylyltransferase 1, choline, beta 1.065E-03 0.4527 4.360E-04 0.5349 1.386E-05 0.5523 
POLR2B 5431 Polymerase (RNA) II (DNA directed) polypeptide B, 140kDa 1.131E-03 0.4511 4.514E-03 0.4753 1.184E-03 0.4605 
EPHA3 2042 EPH receptor A3 1.304E-03 0.4476 1.587E-05 0.6013 5.169E-07 0.6011 
CHIC2 26511 Cysteine-rich hydrophobic domain 2 1.320E-03 0.4472 3.173E-03 0.4843 1.175E-07 0.6202 
FABP7 2173 Fatty acid binding protein 7, brain 1.851E-03 0.4382 6.272E-05 0.5771 8.028E-06 0.5624 
VSNL1 7447 Visinin-like 1 2.843E-03 0.4265 3.315E-03 0.4830 4.998E-05 0.5278 
PDGFRA 5156 Platelet-derived growth factor receptor, alpha polypeptide 3.086E-03 0.4246 2.300E-03 0.4939 9.830E-05 0.5148 
PCDH17 27253 Protocadherin 17 4.341E-03 0.4158 1.990E-03 0.4982 1.607E-04 0.5049 
CHD9 80205 Chromodomain helicase DNA binding protein 9 4.966E-03 0.4126 2.387E-03 0.4927 5.767E-04 0.4784 
VPS35 55737 Vacuolar protein sorting 35 homolog (S. cerevisiae) 5.291E-03 0.4109 4.889E-03 0.4722 1.559E-03 0.4533 
HOXD10 3236 Homeobox D10 8.234E-03 0.3987 8.495E-03 0.4560 1.037E-03 0.4636 
RUFY3 22902 RUN and FYVE domain containing 3 8.560E-03 0.3974 8.640E-03 0.4554 2.763E-05 0.5395 
ZNF436 80818 Zinc finger protein 436 9.047E-03 0.3956 5.526E-04 0.5297 4.998E-05 0.5283 
SOX21 11166 SRY (sex determining region Y)-box 21 9.175E-03 0.3951 1.831E-04 0.5576 1.408E-08 0.6466 
PI15 51050 Peptidase inhibitor 15 9.879E-03 0.3928 2.695E-03 0.4891 1.196E-07 0.6194 
PAX7 5081 Paired box 7 2.540E-11 0.6977 3.669E-03 0.4806     
ZCCHC5 203430 Zinc finger, CCHC domain containing 5 1.898E-09 0.6542 3.170E-03 0.4846     
C9orf135 138255 Chromosome 9 open reading frame 135 1.469E-08 0.6312 9.492E-03 0.4526     
LPPR4 9890 Plasticity related gene 1 8.014E-08 0.6115 9.916E-03 0.4506     
PRDM16 63976 PR domain containing 16 4.799E-06 0.5558 9.364E-03 0.4533     
HOXD11 3237 Homeobox D11 1.696E-05 0.5347 6.414E-03 0.4640     
WBSCR17 64409 Williams-Beuren syndrome chromosome region 17 1.967E-05 0.5322 2.137E-03 0.4960     
135 
IQCG 84223 IQ motif containing G 2.808E-05 0.5249 2.276E-04 0.5517     
RUNX2 860 Runt-related transcription factor 2 1.013E-04 0.5016 3.745E-06 0.6247     
C1orf173 127254 Chromosome 1 open reading frame 173 4.026E-04 0.4741 4.215E-04 0.5357     
COL14A1 7373 Collagen, type XIV, alpha 1 (undulin) 6.513E-04 0.4644 5.366E-03 0.4691     
NR2E1 7101 Nuclear receptor subfamily 2, group E, member 1 8.732E-04 0.4576 1.751E-03 0.5018     
ZFP28 140612 Zinc finger protein 28 homolog (mouse) 1.775E-03 0.4394 7.828E-03 0.4585     
AFF2 2334 AF4/FMR2 family, member 2 4.054E-03 0.4177 5.555E-03 0.4680     
LOC64532
3 645323 Hypothetical LOC645323 4.517E-03 0.4148 6.742E-04 0.5249     
PPP1CB 5500 Protein phosphatase 1, catalytic subunit, beta isoform 6.868E-03 0.4041 8.232E-03 0.4569     
HECTD2 143279 HECT domain containing 2 6.973E-03 0.4037 2.944E-04 0.5450     
CBX1 10951 Chromobox homolog 1 (HP1 beta homolog Drosophila ) 8.693E-03 0.3969 2.787E-03 0.4881     
IGFBP7 3490 Insulin-like growth factor binding protein 7 2.523E-09 0.6504     3.015E-03 0.4365 
LCTL 197021 Lactase-like 1.534E-08 0.6301     4.998E-05 0.5280 
SCN4B 6330 Sodium channel, voltage-gated, type IV, beta 2.432E-08 0.6246     1.567E-03 0.4531 
FAM13C 220965 family with sequence similarity 13, member C 8.338E-08 0.6106     4.916E-08 0.6312 
RNF217 154214 Ring finger protein 217 1.093E-06 0.5767     8.600E-04 0.4692 
TSPAN2 10100 Tetraspanin 2 1.382E-05 0.5381     9.012E-03 0.4043 
PCDHB10 56126 Protocadherin beta 10 1.967E-05 0.5320     6.612E-04 0.4755 
PDZD2 23037 PDZ domain containing 2 2.455E-05 0.5272     8.409E-03 0.4065 
TAB2 23118 TGF-beta activated kinase 1 3.243E-05 0.5221     7.058E-08 0.6265 
ZNF347 84671 Zinc finger protein 347 7.794E-05 0.5064     1.050E-03 0.4630 
LANCL3 347404 LanC lantibiotic synthetase component C-like 3 (bacterial) 1.119E-04 0.4994     1.061E-04 0.5133 
LYPD1 116372 LY6/PLAUR domain containing 1 1.459E-04 0.4940     3.262E-04 0.4909 
FTO 79068 Fat mass and obesity associated 1.769E-04 0.4903     7.967E-05 0.5187 
ZNF528 84436 Zinc finger protein 528 5.882E-04 0.4666     1.184E-03 0.4604 
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CD70 970 CD70 molecule 5.911E-04 0.4664     3.020E-03 0.4363 
KIF5C 3800 Kinesin family member 5C 5.934E-04 0.4662     2.370E-05 0.5425 
PROX1 5629 Prospero homeobox 1 8.494E-04 0.4584     1.481E-03 0.4545 
AIF1L 83543 allograft inflammatory factor 1-like 8.732E-04 0.4576     5.591E-03 0.4193 
HRCT1 646962 histidine rich carboxyl terminus 1 9.025E-04 0.4567     9.680E-06 0.5587 
SERTAD4 56256 SERTA domain containing 4 9.299E-04 0.4558     9.011E-03 0.4045 
SDK1 221935 Sidekick homolog 1, cell adhesion molecule (chicken) 1.113E-03 0.4518     9.863E-03 0.4012 
PDPR 55066 Pyruvate dehydrogenase phosphatase regulatory subunit 1.142E-03 0.4506     5.767E-04 0.4785 
LRCH2 57631 Leucine-rich repeats and calponin homology (CH) domain containing 2 1.214E-03 0.4493     1.567E-03 0.4529 
IGFBP2 3485 Insulin-like growth factor binding protein 2, 36kDa 1.674E-03 0.4415     1.864E-04 0.5022 
SIAH1 6477 Seven in absentia homolog 1 (Drosophila) 1.905E-03 0.4375     6.670E-04 0.4751 
PPP1R14
C 81706 
Protein phosphatase 1, regulatory 
(inhibitor) subunit 14C 1.932E-03 0.4368     5.866E-05 0.5244 
FZR1 51343 Fizzy/cell division cycle 20 related 1 (Drosophila) 2.081E-03 0.4351     2.587E-03 0.4410 
CDON 50937 Cdon homolog (mouse) 2.143E-03 0.4344     2.524E-04 0.4964 
TMEM188 255919 Transmembrane protein 188 2.301E-03 0.4327     3.122E-05 0.5369 
ZNF542 147947 Zinc finger protein 542 2.465E-03 0.4307     9.681E-03 0.4020 
MAP3K4 4216 Mitogen-activated protein kinase kinase kinase 4 2.498E-03 0.4301     2.908E-03 0.4373 
GLRB 2743 Glycine receptor, beta 2.701E-03 0.4279     9.850E-04 0.4657 
GPC4 2239 Glypican 4 2.834E-03 0.4269     9.778E-04 0.4660 
ZNF382 84911 Zinc finger protein 382 2.838E-03 0.4267     7.285E-04 0.4731 
GPM6B 2824 Glycoprotein M6B 3.198E-03 0.4236     1.841E-03 0.4493 
ZNF667 63934 Zinc finger protein 667 3.270E-03 0.4230     7.741E-03 0.4092 
RASGRP3 25780 RAS guanyl releasing protein 3 (calcium and DAG-regulated) 4.078E-03 0.4175     9.571E-05 0.5155 
ZNF536 9745 Zinc finger protein 536 4.174E-03 0.4169     5.767E-04 0.4784 
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PTN 5764 
Pleiotrophin (heparin binding growth 
factor 8, neurite growth-promoting 
factor 1) 
5.095E-03 0.4118     1.024E-03 0.4640 
ADRA1D 146 Adrenergic, alpha-1D-, receptor 5.342E-03 0.4107     2.702E-05 0.5402 
CDH4 1002 Cadherin 4, type 1, R-cadherin (retinal) 6.461E-03 0.4059     1.024E-03 0.4642 
PALLD 23022 Palladin, cytoskeletal associated protein 6.583E-03 0.4053     4.498E-04 0.4841 
GFRA1 2674 GDNF family receptor alpha 1 6.723E-03 0.4047     1.019E-03 0.4645 
UNC5C 8633 Unc-5 homolog C (C. elegans) 7.752E-03 0.4007     4.725E-03 0.4240 
MFSD2A 84879 major facilitator superfamily domain containing 2A 7.861E-03 0.4001     4.059E-06 0.5730 
PTPRB 5787 Protein tyrosine phosphatase, receptor type, B 7.868E-03 0.4000     3.576E-03 0.4314 
SERAC1 84947 Serine active site containing 1 8.002E-03 0.3994     1.531E-04 0.5060 
VEZF1 7716 Vascular endothelial zinc finger 1 9.784E-03 0.3931     1.009E-05 0.5576 
PPFIA2 8499 
Protein tyrosine phosphatase, 
receptor type, f polypeptide (PTPRF), 
interacting protein (liprin), alpha 2 
    3.484E-05 0.5882 1.451E-06 0.5873 
CPA6 57094 Carboxypeptidase A6     5.732E-05 0.5792 2.941E-12 0.7224 
WARS2 10352 Tryptophanyl tRNA synthetase 2, mitochondrial     1.909E-04 0.5555 2.837E-05 0.5387 
KCNIP4 80333 Kv channel interacting protein 4     2.689E-04 0.5473 4.093E-03 0.4283 
PCDH20 64881 Protocadherin 20     3.819E-04 0.5383 6.190E-04 0.4769 
ITM2B 9445 Integral membrane protein 2B     5.937E-04 0.5276 3.830E-03 0.4298 
PRSS12 8492 Protease, serine, 12 (neurotrypsin, motopsin)     2.678E-03 0.4894 1.092E-04 0.5122 
SHCBP1 79801 SHC SH2-domain binding protein 1     2.757E-03 0.4885 4.498E-04 0.4842 
MARCH1 55016 Membrane-associated ring finger (C3HC4) 1     3.170E-03 0.4849 1.404E-05 0.5517 
DYNLL2 140735 Dynein, light chain, LC8-type 2     3.170E-03 0.4847 9.863E-03 0.4013 
PAX6 5080 Paired box 6     4.581E-03 0.4740 5.256E-04 0.4808 
TMEM25 84866 Transmembrane protein 25     8.021E-03 0.4577 4.632E-03 0.4246 
HLF 3131 Hepatic leukemia factor     8.335E-03 0.4565 8.762E-06 0.5605 
NTRK3 4916 Neurotrophic tyrosine kinase, receptor, type 3     9.725E-03 0.4520 3.413E-04 0.4899 
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ZNF226 7769 Zinc finger protein 226     9.746E-03 0.4517 1.469E-03 0.4551 
SUMO2 6613 SMT3 suppressor of mif two 3 homolog 2 (S. cerevisiae)     9.916E-03 0.4505 2.782E-03 0.4388 
 
VSV-VSV∆G infection was analyzed for correlation with gene expression on three different cDNA microarray analyses of the NCI60 
(U133, Agilent, HuEx).  A correlation coefficient (CC) was determined for each gene.  120 genes were correlated with VSV-VSV∆G 
infection based on a CC with a p-value cutoff of p < 0.01 identified on at least 2 of 3 microarrays.  Of these, 38 genes were identified 
on 3 of 3 microarrays, listed at the top of the table.  This list of VSV correlated genes was used as a background list for the further 
analysis of any other Hantavirus-VSV∆G correlations.  Any genes from those lists overlapping with these VSV genes were considered 
non-specific to the Hantavirus and removed from further consideration.
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Appendix B:  Genes correlated with SNV-VSV∆G infection.   
 
Gene Information u133 Agilent HuEx 
Gene 
Symbol 
EntrezGene 
ID Gene Name p-value CC p-value CC p-value CC 
SLC38A3 10991 Solute carrier family 38, member 3 1.720E-09 0.6777 2.550E-05 0.6117 3.840E-16 0.7938 
GPM6A 2823 Glycoprotein M6A 3.450E-08 0.6372 1.670E-06 0.6571 3.320E-11 0.7131 
AMPD1 270 Adenosine monophosphate deaminase 1 (isoform M) 1.110E-06 0.5826 1.270E-03 0.5219 6.360E-08 0.6365 
GFAP 2670 Glial fibrillary acidic protein 3.870E-07 0.6002 1.670E-06 0.6599 8.930E-08 0.6315 
ENPP6 133121 
Ectonucleotide 
pyrophosphatase/phosphodiesteras
e 6 
7.830E-08 0.6260 1.670E-06 0.6655 2.060E-07 0.6199 
CNR1 1268 Cannabinoid receptor 1 (brain) 9.100E-05 0.5086 1.270E-03 0.5206 7.880E-07 0.6023 
PIPOX 51268 Pipecolic acid oxidase 1.980E-07 0.6098 6.070E-03 0.4757 7.880E-07 0.6022 
KIF5C 3800 Kinesin family member 5C 7.644E-04 0.4639 6.822E-03 0.4718 1.430E-05 0.5626 
VSNL1 7447 Visinin-like 1 2.400E-06 0.5689 4.045E-04 0.5551 1.440E-05 0.5614 
ZNF436 80818 Zinc finger protein 436 5.355E-03 0.4099 3.505E-03 0.4913 3.900E-05 0.5442 
LANCL3 347404 LanC lantibiotic synthetase component C-like 3 (bacterial) 2.310E-06 0.5697 5.752E-04 0.5435 4.200E-05 0.5398 
TTLL7 79739 Tubulin tyrosine ligase-like family, member 7 8.156E-03 0.3973 6.070E-03 0.4756 4.890E-05 0.5349 
GRIK4 2900 Glutamate receptor, ionotropic, kainate 4 6.625E-04 0.4680 1.270E-03 0.5214 1.521E-04 0.5121 
PRSS12 8492 Protease, serine, 12 (neurotrypsin, motopsin) 9.154E-03 0.3927 1.166E-03 0.5254 2.221E-04 0.5034 
TMEM25 84866 Transmembrane protein 25 1.043E-03 0.4562 1.822E-03 0.5122 2.922E-04 0.4982 
IQCG 84223 IQ motif containing G 2.690E-06 0.5663 1.039E-04 0.5814 7.096E-04 0.4797 
MAP6D1 79929 MAP6 domain containing 1 1.759E-03 0.4429 6.264E-03 0.4744 8.980E-04 0.4733 
FBXO3 26273 F-box protein 3 5.069E-04 0.4742 8.883E-04 0.5318 9.273E-04 0.4724 
PRSS35 167681 Protease, serine, 35 4.317E-04 0.4774 5.708E-03 0.4777 1.304E-03 0.4636 
EPHA3 2042 EPH receptor A3 2.280E-04 0.4914 8.190E-03 0.4653 2.261E-03 0.4484 
DYNLL2 140735 Dynein, light chain, LC8-type 2 4.499E-03 0.4152 2.500E-03 0.5013 2.374E-03 0.4467 
SLC27A6 28965 Solute carrier family 27 (fatty acid transporter), member 6 1.590E-06 0.5763 4.490E-05 0.5979 6.824E-03 0.4108 
C10orf79 80217 Chromosome 10 open reading 3.632E-04 0.4816 3.562E-04 0.5584     
140 
frame 79 
IRX1 79192 Iroquois homeobox 1 9.820E-07 0.5844 4.796E-04 0.5480     
RUNX2 860 Runt-related transcription factor 2 3.940E-06 0.5609 5.597E-04 0.5444     
HECTD2 143279 HECT domain containing 2 9.970E-04 0.4573 6.005E-04 0.5419     
LPPR4 9890 Plasticity related gene 1 2.020E-06 0.5723 7.158E-04 0.5384     
DLL1 28514 Delta-like 1 (Drosophila) 7.100E-05 0.5136 8.649E-04 0.5327     
RHBDL3 162494 Rhomboid, veinlet-like 3 (Drosophila) 4.611E-03 0.4144 1.822E-03 0.5116     
LRP2BP 55805 LRP2 binding protein 7.780E-05 0.5119 2.727E-03 0.4989     
PRDM16 63976 PR domain containing 16 8.600E-06 0.5490 6.540E-03 0.4733     
KLHL2 11275 Kelch-like 2, Mayven (Drosophila) 1.142E-03 0.4540 8.804E-03 0.4633     
C1orf173 127254 Chromosome 1 open reading frame 173 7.370E-05 0.5129 9.314E-03 0.4615     
HTR7 3363 
5-hydroxytryptamine (serotonin) 
receptor 7 (adenylate cyclase-
coupled) 
1.410E-07 0.6168     4.200E-05 0.5393 
LOC1001
28252 100128252 LOC100128252 1.440E-07 0.6158     9.092E-03 0.4005 
TAB2 23118 TGF-beta activated kinase 1 1.860E-07 0.6123     9.140E-09 0.6596 
KIAA1161 57462 KIAA1161 1.980E-07 0.6101     2.922E-04 0.4975 
RNF217 154214 Ring finger protein 217 6.280E-07 0.5927     3.489E-04 0.4938 
EPHB3 2049 EPH receptor B3 1.370E-06 0.5787     1.521E-04 0.5125 
FAM13C 220965 family with sequence similarity 13, member C 3.810E-06 0.5616     7.910E-05 0.5262 
IGSF3 3321 Immunoglobulin superfamily, member 3 4.400E-06 0.5592     5.229E-03 0.4204 
SOX2OT 347689 SOX2 overlapping transcript (non-protein coding) 5.590E-06 0.5552     8.846E-03 0.4021 
PCDHB10 56126 Protocadherin beta 10 8.720E-06 0.5484     1.755E-04 0.5087 
LCTL 197021 Lactase-like 1.360E-05 0.5409     1.996E-03 0.4535 
TRIM2 23321 Tripartite motif-containing 2 3.640E-05 0.5255     7.876E-03 0.4064 
MFSD2A 84879 major facilitator superfamily domain containing 2A 4.200E-05 0.5232     6.634E-04 0.4812 
LHX2 9355 LIM homeobox 2 6.270E-05 0.5157     9.005E-03 0.4010 
LRIG3 121227 Leucine-rich repeats and immunoglobulin-like domains 3 8.750E-05 0.5098     1.031E-03 0.4690 
C11orf63 79864 Chromosome 11 open reading 8.750E-05 0.5096     2.021E-04 0.5057 
141 
frame 63 
CAPS 828 Calcyphosine 9.100E-05 0.5086     2.918E-04 0.4985 
PALLD 23022 Palladin, cytoskeletal associated protein 1.396E-04 0.5009     8.980E-04 0.4733 
FABP7 2173 Fatty acid binding protein 7, brain 1.788E-04 0.4963     3.547E-03 0.4336 
LRP1B 53353 Low density lipoprotein-related protein 1B (deleted in tumors) 3.242E-04 0.4848     2.039E-04 0.5052 
CUEDC1 404093 CUE domain containing 1 4.053E-04 0.4790     4.890E-05 0.5354 
IGFBP2 3485 Insulin-like growth factor binding protein 2, 36kDa 4.230E-04 0.4779     4.890E-05 0.5350 
FTO 79068 Fat mass and obesity associated 4.454E-04 0.4767     3.032E-04 0.4966 
NDP 4693 Norrie disease (pseudoglioma) 6.341E-04 0.4693     8.005E-03 0.4058 
MAN1A2 10905 Mannosidase, alpha, class 1A, member 2 6.445E-04 0.4689     7.513E-03 0.4080 
CHST1 8534 Carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 6.460E-04 0.4686     9.491E-03 0.3989 
WDR45L 56270 WDR45-like 6.682E-04 0.4675     8.951E-03 0.4016 
MUM1L1 139221 Melanoma associated antigen (mutated) 1-like 1 6.944E-04 0.4667     3.472E-03 0.4354 
FZR1 51343 Fizzy/cell division cycle 20 related 1 (Drosophila) 8.623E-04 0.4611     5.559E-03 0.4181 
FEZ1 9638 Fasciculation and elongation protein zeta 1 (zygin I) 1.136E-03 0.4543     9.453E-04 0.4718 
PPP1R14
C 81706 
Protein phosphatase 1, regulatory 
(inhibitor) subunit 14C 1.196E-03 0.4526     2.409E-03 0.4462 
HOXC13 3229 Homeobox C13 1.318E-03 0.4504     1.410E-05 0.5645 
PTN 5764 
Pleiotrophin (heparin binding growth 
factor 8, neurite growth-promoting 
factor 1) 
1.318E-03 0.4504     4.955E-03 0.4223 
PIP 5304 Prolactin-induced protein 2.210E-03 0.4366     8.634E-03 0.4028 
HRCT1 646962 histidine rich carboxyl terminus 1 2.404E-03 0.4341     3.008E-03 0.4395 
LYPD1 116372 LY6/PLAUR domain containing 1 2.493E-03 0.4332     3.355E-03 0.4366 
SLC22A2
3 63027 solute carrier family 22, member 23 2.674E-03 0.4310     7.100E-05 0.5283 
ZNF415 55786 Zinc finger protein 415 3.056E-03 0.4272     5.198E-03 0.4207 
SPECC1 92521 Sperm antigen with calponin homology and coiled-coil domains 1 3.072E-03 0.4270     8.964E-03 0.4015 
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PPAP2A 8611 Phosphatidic acid phosphatase type 2A 3.148E-03 0.4264     5.363E-03 0.4194 
ADRA1D 146 Adrenergic, alpha-1D-, receptor 3.192E-03 0.4260     3.206E-03 0.4377 
SEC22C 9117 SEC22 vesicle trafficking protein homolog C (S. cerevisiae) 4.010E-03 0.4192     2.860E-03 0.4413 
SYTL5 94122 Synaptotagmin-like 5 4.012E-03 0.4190     4.150E-05 0.5419 
KLHL13 90293 Kelch-like 13 (Drosophila) 4.336E-03 0.4166     8.382E-03 0.4037 
FGFRL1 53834 Fibroblast growth factor receptor-like 1 4.347E-03 0.4164     2.452E-03 0.4455 
AMFR 267 Autocrine motility factor receptor 4.471E-03 0.4154     4.040E-05 0.5430 
C1orf88 128344 Chromosome 1 open reading frame 88 4.611E-03 0.4143     4.482E-03 0.4267 
TFAP2C 7022 
Transcription factor AP-2 gamma 
(activating enhancer binding protein 
2 gamma) 
4.758E-03 0.4133     4.548E-03 0.4251 
HOXD10 3236 Homeobox D10 4.819E-03 0.4130     6.018E-03 0.4145 
CCDC113 29070 Coiled-coil domain containing 113 4.881E-03 0.4124     2.237E-03 0.4488 
CDON 50937 Cdon homolog (mouse) 4.964E-03 0.4119     9.453E-04 0.4708 
RASGRP3 25780 RAS guanyl releasing protein 3 (calcium and DAG-regulated) 5.218E-03 0.4106     9.900E-05 0.5218 
POLR2B 5431 Polymerase (RNA) II (DNA directed) polypeptide B, 140kDa 6.233E-03 0.4054     7.876E-03 0.4065 
USO1 8615 USO1 homolog, vesicle docking protein (yeast) 6.893E-03 0.4025     5.944E-03 0.4153 
DNAJC22 79962 DnaJ (Hsp40) homolog, subfamily C, member 22 7.024E-03 0.4018     1.339E-03 0.4627 
FUNDC1 139341 FUN14 domain containing 1 7.115E-03 0.4014     1.277E-03 0.4645 
ITGB4 3691 Integrin, beta 4 7.636E-03 0.3993     2.548E-03 0.4446 
CLPTM1 1209 Cleft lip and palate associated transmembrane protein 1 8.156E-03 0.3972     3.619E-03 0.4329 
MCC 4163 Mutated in colorectal cancers 8.156E-03 0.3971     6.600E-05 0.5299 
SPAG17 200162 Sperm associated antigen 17     8.332E-04 0.5348 1.840E-08 0.6509 
CPA6 57094 Carboxypeptidase A6     2.275E-03 0.5056 1.310E-07 0.6261 
PPFIA2 8499 
Protein tyrosine phosphatase, 
receptor type, f polypeptide 
(PTPRF), interacting protein (liprin), 
alpha 2 
    1.158E-03 0.5262 8.862E-04 0.4746 
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PDGFRA 5156 Platelet-derived growth factor receptor, alpha polypeptide     5.850E-05 0.5923 5.561E-03 0.4179 
ARL3 403 ADP-ribosylation factor-like 3     7.649E-03 0.4680 4.190E-05 0.5407 
DAPK2 23604 Death-associated protein kinase 2     1.240E-03 0.5233 1.521E-04 0.5120 
NR1D1 9572 Nuclear receptor subfamily 1, group D, member 1     1.670E-06 0.6588 1.521E-04 0.5117 
TP73 7161 Tumor protein p73     3.549E-03 0.4902 2.922E-04 0.4978 
RDX 5962 Radixin     6.980E-03 0.4705 2.957E-03 0.4400 
MGEA5 10724 Meningioma expressed antigen 5 (hyaluronidase)     9.592E-04 0.5301 4.827E-03 0.4232 
ARHGAP
18 93663 Rho GTPase activating protein 18     5.042E-03 0.4810 5.944E-03 0.4152 
HDAC5 10014 Histone deacetylase 5     1.160E-03 0.5259 8.852E-03 0.4019 
ACOX1 51 Acyl-Coenzyme A oxidase 1, palmitoyl     3.793E-03 0.4877 9.242E-03 0.4000 
 
SNV-VSV∆G infection was analyzed for correlation with gene expression on three different cDNA microarray analyses of the NCI60 
(U133, Agilent, HuEx).  A correlation coefficient (CC) was determined for each gene.   
